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Introduction
The inhibition of steroid sulfatase (STS) as a new target for en-
docrine therapy has attracted considerable attention over the
past two decades after recognition that the STS pathway could
also be a significant source of oestrogens alongside those orig-
inating from aromatase, the enzyme that aromatises andro-
gens to oestrogens. Evidence to support this hypothesis in-
cludes: 1) a millionfold higher STS activity than aromatase ac-
tivity in liver as well as normal and malignant breast tissues,
[1]
2) the origin of oestrone (E1) from oestrone sulfate (E1S) in
breast cancer tissue is ~10-fold greater than that from andros-
tenedione,
[2] and 3) STS expression is an important prognostic
factor in human breast carcinoma.
[3,4] Most oestrogens that
originate from the aromatase pathway are converted into and
stored in the body as sulfate conjugates that per se are biolog-
ically inactive. However, this reservoir of oestrogen sulfates
could significantly contribute to overall oestrogenic stimulation
of the growth and development of hormone-dependent tu-
mours when STS catalyses the hydrolysis of substrates such as
E1S to E1, and dehydroepiandrosterone sulfate (DHEA-S) to
DHEA. The formation of DHEA via the STS pathway accounts
for the production of 90% of androstenediol (Adiol). Although
structurally an androgen, Adiol possesses oestrogenic proper-
ties. It is ~100-fold weaker than oestradiol
[5–8] and has a lower
affinity for the oestrogen receptor.
[9] However, the 100-fold
higher concentrations of Adiol in the circulation have led some
to speculate that it may have oestrogenic properties equipo-
tent to oestradiol.
[10] Thus, STS is an attractive and novel target
for rendering potentially more effective oestrogen deprivation
through therapeutic intervention in hormone-dependent can-
cers such as those of the breast, endometrium, and prostate.
Considerable progress has been made since the early 1990s
in the development of STS inhibitors. Many structurally (steroi-
dal and nonsteroidal) and mechanistically (principally reversible
and irreversible) diverse inhibitors have been developed. How-
ever, compounds that contain the pharmacophore for irreversi-
ble inhibition of STS, i.e., an aryl sulfamate ester, have consis-
tently shown distinctive and potent in vitro and in vivo inhibi-
tory activities.
[11–13] One compound, the nonsteroidal inhibitor 1
(Irosustat, STX64, BN83495, Figure 1), is the first STS inhibitor
to enter clinical trials for postmenopausal patients with ad-
Structure–activity relationship studies were conducted on Iro-
sustat (STX64, BN83495), the first steroid sulfatase (STS) inhibi-
tor to enter diverse clinical trials for patients with advanced
hormone-dependent cancer. The size of its aliphatic ring was
expanded; its sulfamate group was N,N-dimethylated, relocat-
ed to another position and flanked by an adjacent methoxy
group; and series of quinolin-2(1H)-one and quinoline deriva-
tives of Irosustat were explored. The STS inhibitory activities of
the synthesised compounds were assessed in a preparation of
JEG-3 cells. Stepwise enlargement of the aliphatic ring from 7
to 11 members increases potency, although a further increase
in ring size is detrimental. The best STS inhibitors in vitro had
IC50 values between 0.015 and 0.025 nm. Other modifications
made to Irosustat were found to either abolish or significantly
weaken its activity. An azomethine adduct of Irosustat with
N,N-dimethylformamide (DMF) was isolated, and crystal struc-
tures of Irosustat and this adduct were determined. Docking
studies were conducted to explore the potential interactions
between compounds and the active site of STS, and suggest a
sulfamoyl group transfer to formylglycine 75 during the inacti-
vation mechanism.
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couraging results.
[14,15] Progress has been made since the com-
pletion of this first trial.
[16] Currently, 1 is undergoing phase I
trials for advanced prostate cancer and phase II trials for endo-
metrial and advanced breast cancer.
On the discovery of 1 as a potent STS inhibitor, a basic
study was carried out to provide a preliminary structure–activi-
ty relationship (SAR).
[17] The main focus of that work was on
ring contraction (from 7- down to 6- and 5-membered rings:
compounds 2 and 3, Figure 1) and expansion (from 7- to 8-
membered rings: 4, Figure 1) of the aliphatic ring of 1. In addi-
tion, a tricyclic oxepin derivative of 3 (compound 5, Figure 1)
was synthesised and evaluated. Herein we report a more ex-
tensive SAR study for 1, further expansion of the aliphatic ring
size, N,N-dimethylation of the sulfamate group, relocation of
the sulfamate group to another position, introduction of a sub-
stituent adjacent to the sulfamate group, and exploration of a
series of quinolin-2(1H)-one and quinoline derivatives of 1. The
biological activities of the synthesised compounds were as-
sessed in a preparation of JEG-3 cells. In addition, an azome-
thine adduct of 1 and N,N-dimethylformamide (DMF) is report-
ed. The crystal structures of 1 and its azomethine adduct were
determined. Docking studies were conducted to explore the




With the exception of ethyl 2-oxocyclotridecanecarboxylate,
which is available commercially, the starting cyclic b-keto
esters required for the synthesis of tricyclic coumarins 6b–9b
and 11b were prepared by treating the corresponding cyclo-
alkyl ketone with diethyl carbonate in the presence of two
equivalents of sodium hydride at room temperature.
[18] The
parent tricyclic coumarins were formed under Pechmann con-
ditions by cyclising resorcinol and the corresponding ethyl 2-
oxocycloalkylcarboxylates in the presence of an equimolar mix-
ture of trifluoroacetic acid and concentrated sulfuric acid as
the condensing agent (Scheme 1). The yields of the tricyclic
coumarins ranged from 14 to 33%, presumably due to severe
ring strain experienced by cycloalkenyl rings, in particular cy-
clononene and cycloundecene, during the cyclisation of the
cyclic b-keto esters with resorcinol.
An earlier method was used for the sulfamoylation of parent
hydroxycoumarins (Scheme 1). This involved treating a solution
of the phenol in anhydrous N,N-dimethylformamide (DMF)
with sodium hydride followed by the addition of a freshly con-
centrated solution of sulfamoyl chloride in toluene, which was
prepared according to the method of Woo et al.
[19]
The synthesis of 12 was initially attempted by deprotonation
of 1 in N,N-dimethylacetamide (DMA) with sodium hydride at
08C followed by N,N-dimethylation with methyl iodide
(Scheme 2). However, compound 12 obtained by this route
was persistently contaminated by a trace amount of 3-
methoxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one,
which is most likely the product of desulfamoylation of 1 fol-
lowed by methylation of the phenol released (compound 1a)
under the reaction conditions employed. This ethereal contam-
inant was particularly difficult to remove, and hence a different
synthetic approach was sought. Compound 12 was subse-
quently prepared with high purity by heating 1a in N,N-di-
methylcyclohexylamine with N,N-dimethylsulfonyl chloride
(Scheme 2).
Figure 1. Structure of 1 (Irosustat, STX64), 1a(the parent phenol of 1), and
derivatives 2–5.
Scheme 1. Synthesis of tricyclic coumarin sulfamates (6–11). Reagents and
conditions: a) 2NaH, N2, 15 h, RT; b) concd H2SO4/CF3COOH, 3 h, 08C!RT;
c) anhydrous DMF, NaH, N2,H 2NSO2Cl, 08C!RT.
Scheme 2. Synthesis of 12, the N,N-dimethyl derivative of 1. Reagents and
conditions: a) NaH, CH3I, 08C( 12 obtained in this manner was contaminated
by a trace amount of the 3-methoxy derivative of 1a);b )N,N-dimethylcyclo-
hexylamine, Me2NSO2Cl, 90–958C, 1 h.
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mann route, although resorcinol was replaced by 4-methoxy-
benzene-1,3-diol (13a) as starting material, which was pre-
pared according to the method of Godfrey et al. (Scheme 3).
[20]
Sulfamoylation of a solution of 13b in DMA gave the methoxy-
lated tricyclic coumarin sulfamate 13.
The synthesis of 2-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]-
chromen-6(7H)-one (14a) was carried out by allowing hydro-
quinone to react with methyl 2-oxo-1-cycloheptanecarboxylate
under Pechmann conditions (Scheme 4). As anticipated, the
isolated yield of 14a was extremely low (3%) due to
the 2-position of hydroquinone not being electron-
rich and hence activated for ring closure by a Pech-
mann mechanism. Nonetheless, a sufficient quantity
of 14a was isolated for further sulfamoylation to give
the 2-sulfamate 14.
Compound 15 is a low-yielding azomethine adduct
of 1 with DMF. Only a very small amount of 15 was
isolated during a very large-scale synthesis of 1 that
was performed for determination of its crystal struc-
ture. With an earlier method for conducting sulfa-
moylation, which involves the use of sodium hydride
in excess for deprotonating the phenolic parent com-
pound 1a in DMF prior to the addition of sulfamoyl
chloride, the formation of 15 is anticipated, as we re-
ported earlier a similar azomethine adduct between
2-nitrophenyl sulfamate and DMF.
[21] It is reasoned
that the presence of excess sodium hydride in the re-
action mixture deprotonates the sulfamate group of
1 after its formation, and the resulting anion under-
goes a nucleophilic attack on the formyl group of DMF to give
compound 15 upon subsequent dehydration, as illustrated in
Scheme 5.
The quinolinone derivative 16a was prepared in good yield
(73%) by heating a mixture of 3-aminophenol and methyl 3-
oxo-1-cycloheptane carboxylate (Scheme 6). Sulfamoylation of
16a in the usual manner gave the quinolinone sulfamate 16.
The key intermediate for synthesising the rest of the quino-
line and quinolinone derivatives reported herein is compound
17, which was prepared by O-benzyl protection of 16a
(Scheme 6). After deprotonation of 17 with sodium hydride
and heating the resulting anion with methyl iodide, the N-
methyl derivative 18a was obtained in high yield. Debenzyla-
tion by hydrogenation gave the phenolic quinolinone 18b,
which was sulfamoylated to give the 5-methyl quinolinone sul-
famate 18.
The 3-O-benzyl-protected quinolinone 17 was converted
into the 6-chloroquinoline 19a with phosphorus oxychloride.
Holding 19a at reflux in anhydrous DMF with freshly prepared
sodium methoxide gave the 6-methoxyquinoline 19b. The 6-
methylquinolinyl sulfamate 19 was obtained by first debenzy-
lating 19b followed by sulfamoylating the phenolic derivative
19c.
Quinolinones 20 and 22 and quinolines 21 and 23 were pre-
pared by a different route from their corresponding lower
members 18 and 19. Holding the anion of 17 at reflux in DMF
with either 1-bromopentane or 1-bromo-3-phenylpropane ren-
dered a mixture of both the N- (20a and 22a) and O-alkylated
(21a and 23a) derivatives. Interestingly, the isolated yields of
quinolinones 20a (62%) and 22a (55%) were both found to
be higher than their quinoline counterparts 21a (41%) and
23a (42%), suggesting that N-alkylation is slightly more fa-
vourable under the reaction conditions. In addition, both qui-
nolinones were retained longer by silica in flash chromatogra-
phy than quinolines, suggesting that 20a and 22a are more
polar than 21a and 23a. Debenzylation by hydrogenation of
20a–23a in the usual manner gave the phenolic derivatives
Scheme 4. Synthesis of compound 14. Reagents and conditions: a) concd
H2SO4/CF3COOH, 08C!RT, 60 h; b) anhydrous DMA, N2,H 2NSO2Cl, 08C!RT.
Scheme 3. Synthesis of compound 13. Reagents and conditions: a) concd
H2SO4/CF3COOH, 08C!RT, 60 h; b) anhydrous DMA, N2,H 2NSO2Cl, 08C!RT.
Scheme 5. Proposed mechanism for the formation of 15, an azomethine adduct between
compound 1 and DMF.
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Irosustat SAR20b–23b, which upon sulfamoylation gave the corresponding
sulfamates 20–23.
The aminoquinolinone 24a was prepared by heating a mix-
ture of 1,3-phenylenediamine and methyl 2-oxo-1-cyclohep-
tane carboxylate at 1508C overnight (Scheme 7). Upon sulfa-
moylation of a solution of 24a in DMF in the presence of 2,6-
di-tert-butyl-4-methylpyridine (DBMP) and sulfamoyl chloride
gave the sulfamido quinolinone 24.
Crystal structures
A crystal of 1 with approximate dimensions of 0.25 0.10 
0.08 mm was used for data collection. As shown in Figure 2b,
molecules of 1 interact via a net-
work of intermolecular hydrogen
bonds. In particular, one proton
of the sulfamate NH2 group
(H1B) interacts with the carbonyl
oxygen atom (O5) of the cou-
marin ring in a proximate mole-
cule, whereas the other NH
proton (H1A) interacts with an
oxygen atom (O2) of the SO2
group of a neighbouring sulfa-
mate group. Additionally, there
are possible intermolecular p–p
interactions present (centroidC9-
C10-C15-C16 to centroidC1-C2-C3-C4-C5-C6
distance=3.52  ). As predicted
in previous work by molecular
modelling, the 7-membered ali-
phatic ring of 1 is in the chair
form (Figure 2a,b), which is simi-
lar to that of cycloheptene with
the C=C moiety taking the place
of one of the ring carbon atoms
in the cyclohexane chair.
[17]
A crystal of 15 with approxi-
mate dimensions of 0.25 0.13 
0.10 mm was used for data col-
lection. As shown in Figure 2c,
the tricyclic coumarin scaffold of
15 has a similar conformation to
that observed for 1. The stereo-
chemistry is unambiguously E at the double bond of its (di-
methylamino)methylene sulfamoyl group, suggesting that
steric effects might be a contributing factor in the more fa-
vourable formation of the trans geometric isomer via the route
in Scheme 5, with the bulky dimethylamino and arylsulfamoyl
motifs placed diametrically opposite before the antiperiplanar
elimination of water. As for 1, the aliphatic ring of 15 is clearly
in the chair form. Crystal structures of two other tricyclic cou-
marin sulfamates 6 and 7 with larger ring sizes were also ob-
tained and have been reported elsewhere.
[22]
Structure–activity relationship and molecular modelling
Altogether, ten tricyclic coumarin sulfamates are compared in
this work, out of which the syntheses of six final compounds
are reported for the first time. These compounds contain a
core bicyclic coumarin ring system, but differ in the size of the
third (aliphatic) ring. The lowest member of the series studied
is 2, because having an aliphatic ring smaller than the 5-mem-
bered cyclopentenyl would be synthetically challenging due to
the significant ring strain of a cyclobutene or cyclopropene.
The increase in size of the third ring was carried out in a step-
wise fashion from 5 to 15 members, although the 14-mem-
bered derivative was omitted, primarily due to the lack of com-
mercial availability of cyclotetradecanone as starting material.
Scheme 6. Synthesis of quinoline and quinolinone derivatives of 1. Reagents and conditions: a) 1508C, 8 h; b) an-
hydrous DMF, NaH, N2,H 2NSO2Cl, 08C!RT; c) NaH, DMF, 08C, BnBr, 908C; d) NaH, DMF, 08C, CH3I, 808C; e) Pd/C
(10%), THF, H2 (balloon); f) POCl3, reflux; g) anhydrous DMF, NaH, anhydrous MeOH/DMF, 708C, 2 h; h) Pd/C (10%),
abs. EtOH, H2 (balloon); i) 2,6-di-tert-butyl-4-methylpyridine, N2, anhydrous CH2Cl2,H 2NSO2Cl, RT; j) NaH, anhydrous
DMF, 1-bromopentane or 1-bromo-3-phenylpropane, 1008C, 1 h [X=OSO2NH2].
Scheme 7. Synthesis of compound 24. Reagents and conditions: a) 1508C,
18 h; b) anhydrous DMF, N2, DBMP, H2NSO2Cl, 08C!RT.
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marin sulfamates 1–4 and 6–11 in a placental microsome prep-
aration, and the results were reported in a previous publica-
tion.
[23] For reference and comparison, these results are listed
in Table 1. In this assay, 7 (10-membered third ring) proved to
be the most potent STS inhibitor of the series in vitro, with an
IC50 value of 1 nm, although 1 (7-membered third ring), 6 (9-
membered third ring), and 8 (11-membered third ring) were
also potent, with IC50 values ranging from 8 to 13 nm. The
least potent congeners of the series were 2 (5-membered third
ring) and 11 (15-membered third ring), the IC50 values for
which were found to be 200 nm or higher. While it is not clear
why the IC50 value for 4 (8-membered third ring) is not of the
same order of magnitude as its immediate lower (1) and
higher (6) congeners, but is instead significantly higher at
30 nm, it is apparent that the size of the third ring in this series
of compounds has a marked effect on the potency of com-
pounds against STS. Interestingly, it was found that 7 is only
marginally more potent than 1 in vivo despite its IC50 value in
placental microsomes at 1 nm being eightfold lower than that
of 1.
[23] Despite its relatively weak activity in vitro (IC50=
370 nm, placental microsomes), 11 was found to be the most
potent tricyclic coumarin sulfamate in vivo, inhibiting rat liver
STS activity by 23 and 94% when assayed 24 h after adminis-
tration at respective doses of 0.1 and 1 mgkg
 1,
[23] which may
be explained, among other things, by a depot effect relating
to its high logP value.
We recently replaced the placental microsome preparation
with a JEG-3 cell preparation as the standard assay for screen-
ing the in vitro STS inhibitory activities of compounds. The ad-
vantage of using intact growing JEG-3 cells is that they allow
testing of the compounds under conditions that closely resem-
ble the tissue/physiological situation in which the drug must
first cross the plasma membrane before it can reach the target
(STS) enzyme. These human choriocarcinoma cells have abun-
dant STS enzyme activity, are easy to grow, and are less expen-
sive to use than purified enzyme or placental microsomes. We
therefore re-tested the STS inhibitory activities of the tricyclic
coumarin sulfamates in JEG-3 cells, and their IC50 values are
listed in Table 1. As expected for a cell-based assay, the IC50
values against STS obtained for the series of compounds are
much lower than those obtained from the cell-free placental
microsome assay. However, the overall in vitro inhibitory profile
observed is similar, with potency increasing as the size of the
third aliphatic ring increases from 5 to 11 members, but then
decreasing as the ring size increases further. The most potent
compounds observed are 6–8, the IC50 values of which are be-
tween 0.015 and 0.025 nm, whereas 11 is the weakest STS in-
hibitor in vitro. These results suggest that the ability of com-
pounds to cross the cell membrane and then to interact with
the active site of STS is optimal with compounds 6–8, when
the aliphatic ring contains 8–10 carbon atoms. Unexpectedly,
there is a dramatic decrease in potency observed when the
size of the third ring increases from 11 to 12 members. There
is a five orders of magnitude difference between the IC50
values of 8 and 9.
To examine the possible interactions of tricyclic coumarin
derivatives with amino acid residues within the active site of
STS, these molecules were docked into the crystal structure of
STS (PDB ID: 1P49).
[24] Importantly, the poses discussed are as-
sumed to be those that form immediately prior to the irreversi-
ble inactivation of the enzyme by sulfamoyl transfer. Although
it is currently not known what residue is involved, these dock-
ing results would be predictive of inactivation of the gem-diol
form of the formylglycine residue 75 (FG75) by sulfamoyl trans-
fer. The docking results for 1, 7, and 9 are shown in Figure 3a
and those for 7 and 11 in Figure 3b. In common with 1 and 7,
as shown in Figure 3a, the rest of the compounds in the
series, apart from compound 11, bind with the sulfamate
down by the catalytically crucial FG75 residue and the calcium
ion. This leaves the third aliphatic ring residing in a predomi-
nantly hydrophobic pocket formed by R98, T99, L103, V177,
F178, T180, G181, T484, H485, V486, F488, and F553. As the
Figure 2. a) X-ray crystal structure of 1 (CCDC deposition code: 826524); el-
lipsoids are represented at 30% probability. b) Portion of extended structure
present in 1 showing the network of intermolecular hydrogen bonding. c) X-
ray crystal structure of 15 (CCDC deposition code: 826525); ellipsoids are
represented at 30% probability.
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pounds 1–4 and 6–8), it gives a more favourable contact with
these residues, with the first and second rings (the coumarin
moiety) and the sulfamate occupying nearly identical positions.
This may partly explain the increase in potency of these com-
pounds in general as the third aliphatic ring increases in size.
As shown in Figure 3a, and exemplified by compounds 1 and
7, the carbonyl groups of these compounds are within hydro-
gen bonding distance from the backbone NH group of G100
(~3  ). This additional interaction may be a contributing factor
that further assists the binding of these molecules to the
enzyme active site. The docking pose of compound 9 (12-
membered third ring) is different from that of its lower conge-
ners. Presumably due to steric hindrance rendered by the bulk
of its third ring, 9 binds with the coumarin ring rotated in the
binding site (Figure 3a). As a result, its carbonyl group is no
longer positioned to form a hydrogen bond to G100. The
same observations can be made for compound 10 (13-mem-
bered third ring), as it shows a docking pose similar to that of
compound 9 (not shown). With compound 11, the 15-mem-
bered third ring is too large to fit in the binding site in the
same orientation as it does for compounds 1–4 and 6–10.I n
contrast to its congeners, 11 binds upside down in the binding
site (Figure 3b) which is a much poorer binding pose. The
GOLD docking scores for compounds 1–4 and 6–10 are all in
the range of 52–57 which are not sufficiently different to allow
any correlation to be made between their docking poses and
IC50 values. However, 11 has a
significantly lower GOLD docking
score of 38 which may reflect
the much poorer IC50 observed
for this compound.
The N,N-dimethylation of 1 to
give compound 12 renders the
compound inactive in vitro as an
STS inhibitor (Table 1). This sup-
ports previous findings that a
free sulfamate group is a prereq-
uisite for potent irreversible in-




[25] and N,N-dimethyl de-
rivatives of oestrone 3-O-sulfa-
mate (EMATE)
[26] were found to
be weak reversible or inactive in-
hibitors of STS in placental mi-
crosomes. Only N-acetylated
EMATE, but not the benzoyl de-
rivative, inhibits STS irreversibly,
albeit much less potently than
EMATE.
[25] However, compound
12 was found to behave differ-
ently in vivo. When administered
orally to nude mice, 12 inhibits
liver STS activity potently at
doses of 1 and 10 mgkg
 1.
[27]
Moreover, if 12 is applied topi-
cally at 1 and 10 mgkg
 1, it also inhibits skin as well as liver
STS effectively.
[27] This shows that 12 is able to be absorbed via
the percutaneous route and could then inhibit STS in the liver
and possibly in other tissues throughout the body. We reason
that demethylation of 12 occurs enzymatically in vivo, releas-
ing 1 which is then the agent that inhibits STS.
Keeping a free sulfamate group at the 3-position of 1 but in-
troducing a methoxy group at the 2-position renders the re-
sulting compound 13 a weaker STS inhibitor in JEG-3 cells
(IC50=78 nm for 13 versus 1.5 nm for 1, Table 1). A similar pat-
tern was observed with 2-methoxyestrone 3-O-sulfamate
(IC50=30 nm), which was found to be a weaker STS inhibitor
than EMATE (IC50=4n m) in a preparation of placental micro-
somes.
[28] Having a bulkier aliphatic substituent positioned
next to an aryl sulfamate has also been found to confer
weaker inhibition of STS, presumably due to steric hin-
drance.
[28]
The relocation of the sulfamate group in 1 from the 3- to
the 2-position renders a significant decrease in STS inhibitory
activity of the resulting compound 14 (Table 1). It is reasoned
that the high inhibitory activity observed for 1 is due to its sul-
famate group being in a position conjugated to the a,b-unsa-
turated lactone moiety of the coumarin ring. As a result, the
parent phenol 1a has a lower pKa value and is hence a better
leaving group than unsubstituted phenol. We postulate that
this effect would more effectively facilitate the transfer of the
sulfamoyl group of 1 to an essential amino acid residue in the
Table 1. Inhibition of STS activity in placental microsomes (PM) and JEG-3 cells by tricyclic coumarin sulfamates
1–4 and 6–11, the N,N-dimethyl derivative of 1 (compound 12), the 2-methoxy derivative of 1 (13), 6-oxo-
6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfamate (14), and the azomethine adduct of 1 and DMF
(15).
Compd n PM IC50 [nm]
[a] JEG-3 IC50 [nm]
2 3 200 32
3 47 0 7
1 5 8 1.5
4 6 30 0.9
6 7 2.4 0.022
7 8 1 0.025
8 9 13 0.015
9 10 60 100
10 11 75 220
11 13 370 1600
12 NA ND >10000
13 NA ND 78 13
14 NA ND 283 66
[a] Data from Ref. [23]. Unless stated otherwise, errors are <5% of the reported value (from triplicate experi-
ments); NA: not applicable; ND: not determined.
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tion of the sulfamate group from the 3- to the 2-position to
give 14 would essentially disrupt this process, as the pKa of the
parent phenol 14a is expected to be close to that of unsubsti-
tuted phenol. It is also possible that a sulfamate group placed
at the 2-position might not be presented properly and effec-
tively to essential amino acid residue(s) in the enzyme catalytic
site responsible for its subsequent activation, resulting in less
effective inactivation of the enzyme.
The coumarin moiety has been the core bicyclic template
for the development of nonsteroidal STS inhibitors by our re-
search group. Other phenols of bicyclic nonsteroidal moieties
such as tetrahydronaphthalene;
[26] flavones, isoflavones, flava-
nones;
[29,30] and chromenone and thiochromenone
[31] have also
been sulfamoylated and explored by us and other research
groups for designing STS inhibitors with varying degrees of
success. In this work, we studied the effects of replacing the
coumarin ring system of 1 with either a quinolin-2(1H)-one or
a quinoline moiety. Their respective N-alkylated and alkoxyl de-
rivatives were also investigated for STS inhibitory activity. As
shown in Table 2, all compounds inhibit STS weakly in JEG-3
cells. The best STS inhibitor is the unsubstituted quinolinone
derivative 16 (IC50=240 nm or 98% inhibition at 10 mm), al-
though it is 160-fold less potent than 1 (IC50=1.5 nm, Table 1).
This is closely followed by the quinoline derivative 19, which
inhibits STS by 68% at 10 mm, although the inhibition remains
weak. These results further confirm that the coumarin ring is
essential for the potent STS inhibitory activity observed for 1.
This is attributed to several factors. With 16, 18,a n d19
docked into the STS active site in a fashion similar to that of 7
(Figure 4), we postulate that electronic factors such as the pKa
values of parent phenols could play a significant role for the
results observed. To explore this possible causative factor fur-
ther, the pKa values of 7-hydroxy-2H-chromen-2-one (25, repre-
sents 1a, the parent phenol of 1), 7-hydroxyquinolin-2(1H)-one
(26, represents 16a, the parent phenol of 16), 7-hydroxy-1,4-di-
methylquinolin-2(1H)-one (27, represents 18b, the parent
phenol of 18), and 7-methoxynaphthalen-2-ol (28, represents
19c, the parent phenol of 19) as calculated by ACD/Labs soft-
ware version 11.01 were compared (Figure 5). As shown, the
pKa value of 1a is expected to be between 1 and 2 log units
lower than those of 16a, 18b, and 19c. This factor suggests
that 1a is a much better leaving group than 16a, 18b, and
19c, rendering the sulfamate group of 1aa much stronger sul-
famoylating species for the inactivation of the enzyme, and
hence 1 is a more potent STS inhibitor than the quinolinone
and quinoline derivatives.
Figure 3. The docking of a) 1 (orange), 7 (cyan), and 9 (pink); and b) 7 (cyan)
and 11 (pink) into the crystal structure of human STS. The Ca
2+ ion is depict-
ed as a yellow sphere, and FG75 is the gem-diol form of FG75. Dotted line:
potential hydrogen bond.
Table 2. Inhibition of STS activity in JEG-3 cells by tricyclic quinolinone
sulfamates 16, 18, 20, and 22, tricyclic quinoline sulfamates 19, 21, and
23, and the tricyclic quinolinone sulfamide 24.
Compd R Inhibition [%]
[a,b] IC50 [nm]
[b]
16 H 96 240 40
18 Me ND 2400
19 Me 68 ND
20 (CH2)4CH3 <10 ND
21 (CH2)4CH3 <10 ND
22 (CH2)3Ph 20 ND
23 (CH2)3Ph <10 ND
24 ND ND >10
3
[a] Determined at 10 mm. [b] Unless stated otherwise, errors are <5% of
the reported value (from triplicate experiments); ND: not determined.
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Irosustat SARN-Methylation of 16 to give 18 (IC50=2400 nm, Table 2) is
detrimental to activity, as this substitution produces a 100-fold
decrease in the IC50 value observed for 18 against STS. For
both quinolinone and quinoline series, further enlargement of
the substituent from a methyl group to either an n-pentyl or a
phenethyl group significantly abolishes the STS inhibitory ac-
tivities of the resulting compounds. It is possible that these
substituted molecules no longer bind effectively to the active
site of STS due to steric hindrance caused by the bulk of the
substituent.
Finally, replacement of the bridging oxygen atom of the sul-
famate group in 16 with an NH moiety to give a sulfamido
group abolishes the activity of the resulting compound 24 as
an STS inhibitor. A similar finding was observed with oestrone
3-sulfamide.
[19] We postulate that, unlike the sulfamate group
of 16, an enzyme-catalysed breaking of the S N bond of the
sulfamido group of 24 is unlikely to take place because,
among other things, the parent amine 24a is a very poor leav-
ing group. As a result, it is not anticipated that 24 would be
able to inactivate STS to any degree by sulfamoylating the
active site, but such an approach could provide leads for rever-
sible STS inhibitors.
Conclusions
The nonsteroidal inhibitor Irosustat, STX64 (1) is the first agent
to enter clinical trials for postmenopausal patients with ad-
vanced hormone-dependent breast cancer, and has shown en-
couraging results. In this work, we conducted a range of SAR
studies on this drug. Expansion of the size of the aliphatic ring
of 1 generally provides more potent derivatives against STS in
JEG-3 cells, with best activities observed if the ring is between
9 and 11 members. However, further increasing the ring size is
unfavourable, as inhibitory activities were observed to drop
significantly. Molecular docking studies suggest that the ali-
phatic ring of 1 and its derivatives sit in a hydrophobic pocket
within the enzyme active site with better contacts made with
the enclosing amino acid residues as the ring size increases up
to 11 members. Larger derivatives 9 and 10, and in particular
11, dock less well into the active site. Positioning of the sulfa-
mate moiety close to the catalytic FG75 may be predictive of
sulfamoyl transfer to this residue in the inactivation process.
N,N-Dimethylation of the sulfamate group of 1 is detrimental
to in vitro activity, as compound 12 is inactive. This supports
previous findings which showed that a free sulfamate group
(H2NSO2O
 ) is a prerequisite for potent and irreversible STS in-
hibition. Introducing a methoxy group at the 2-position of 1
significantly decreases the activity of the resulting 13, probably
as a result of steric factors. A detrimental effect to activity is
also observed with relocation of the sulfamate group of 1
from the 3- to the 2-position of the molecule. We postulate
that the decrease in activity of compound 14 is due to its sul-
famate group not being in a conjugated position to the a,b-
unsaturated lactone moiety of the coumarin ring, which affects
the ability of 14 to sulfamoylate and inactivate the enzyme. An
azomethine adduct between 1 and the solvent DMF used in
the sulfamoylation of 1a was isolated. Its crystal structure
shows that the stereochemistry is E at the double bond of its
(dimethylamino)methylene sulfamoyl group. Replacing the
coumarin ring system of 1 to give a series of quinolin-2(1H)-
one and quinoline derivatives produces essentially weak inhibi-
tors of STS. Only the lowest members of the series inhibit STS.
This confirms the unique property of the coumarin system in
the design of nonsteroidal STS inhibitors that are structurally
related to 1.
In summary, most of the modifications made to the clinical
drug 1 decrease potency in vitro. Only a moderate enlarge-
ment of its aliphatic ring results in derivatives that are more
potent STS inhibitors in vitro. However, it remains to be ex-
plored whether such compounds would show significant ad-
vantages over 1 if put through pre-clinical trial development.
Figure 4. The docking of 7 (cyan), 16 (pink), 18 (orange), and 19 (yellow)
into the crystal structure of human STS. The Ca
2+ ion is depicted as a yellow
sphere, and FG75 is the gem-diol form of FG75. Dotted line: potential hydro-
gen bond.
Figure 5. Calculated pKa values of various bicyclic phenols 25–28, which rep-
resent the parent phenols of 1, 16, 18, and 19, respectively. The calculation
was performed by ACD/Labs software version 11.01.
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In vitro sulfatase assay: Biological assays were performed essen-
tially as described previously.
[32] The extent of in vitro inhibition of
STS activities was assessed by using intact monolayers of JEG-3
human choriocarcinoma cells. STS activity was measured with [6,7-
3H]E1S (50 Cimmol
 1, PerkinElmer Life Sciences) over a 1 h period.
Molecular modelling: All ligands were built and minimised using
Schrçdinger software running under Maestro version 9.0. The crys-
tal structure of human placental oestrone/DHEA sulfatase (PDB ID:
1P49)
[24] was used for building the gem-diol form of STS. This in-
volved a point mutation of the ALS75 residue in the crystal struc-
ture to the gem-diol form of the structure using editing tools
within the Schrçdinger software. The resulting structure was then
minimised with the backbone atoms fixed to allow the gem-diol
and surrounding side chain atoms to adopt low-energy confirma-
tions. GOLD was used to dock the ligands 25 times each into the
rigid protein, with the binding site being defined as a 10   sphere
around the ALS75 sulfate. The docked poses were scored using the
GOLDScore fitness function.
General methods for synthesis: All chemicals were purchased
from either Aldrich Chemical Co. (Gillingham, UK) or Alfa Aesar
(Heysham, UK). All organic solvents of analytical reagent grade
were supplied by Fisher Scientific (Loughborough, UK). Anhydrous
N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), and
tetrahydrofuran (THF) were purchased from Aldrich. Sulfamoyl
chloride was prepared by an adaptation of the method of Appel
and Berger
[33] and was stored as a solution under N2 in toluene as
described by Woo et al.
[19]
Thin-layer chromatography (TLC) was performed on pre-coated
plates (Merck TLC aluminium sheets silica gel 60 F254, Art. No.
5554). Product(s) and starting material were detected by viewing
under UV light and/or treating with a methanolic solution of phos-
phomolybdic acid followed by heating. Flash column chromatogra-
phy was performed using gradient elution (solvents indicated in
the text) on wet-packed silica gel (Sorbsil C60). IR spectra were de-
termined with a PerkinElmer 782 infrared spectrophotometer, and
peak positions are expressed in cm
 1.
1H and
13C NMR spectra were
recorded with either a Jeol Delta 270 MHz or a Varian Mercury VX
400 MHz spectrometer. Chemical shifts (d) are reported in parts
per million (ppm) relative to tetramethylsilane (TMS) as an internal
standard. Coupling constants (J) are recorded to the nearest
0.1 Hz. Mass spectra were recorded at the Mass Spectrometry Ser-
vice Centre, University of Bath. FAB mass spectra were measured
using m-nitrobenzyl alcohol as the matrix. Elemental analyses were
performed by the Microanalysis Service, University of Bath. Melting
points were determined using a Reichert–Jung Thermo Galen
Kofler block and are uncorrected. HPLC was undertaken using a
Waters 717 instrument equipped with an autosampler and PDA de-
tector. The column used, conditions of elution, and purity of
sample are as indicated for each compound analysed.
Crystallographic data: CCDC 826524 (1) and 826525 (15) contain
the supplementary crystallographic data for this paper. These data
can be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre via www.ccdc.cam.ac.uk/data_request/cif
Ethyl 2-oxocyclononanecarboxylate (6a). A solution of cyclonona-
none (3.0 g, 21 mmol) in diethyl carbonate (20 mL) was added
dropwise to a suspension of NaH (60% dispersion in mineral oil,
1.71 g, 42.8 mmol) and diethyl carbonate (80 mL) under N2 over a
period of 30 min. When the evolution of H2 had ceased (~15 h),
aqueous HCl (1m, 100 mL) was added in portions, and the result-
ing mixture was extracted with Et2O (3 100 mL). The combined
ethereal extracts were dried (MgSO4) and evaporated to give a
yellow oily residue, which was purified by distillation under re-
duced pressure to give 6a as a clear oil (4.15 g, 91%): Rf=0.72
(CHCl3); bp3: 146–1508C; (Lit. [34] bp2: 108–1108C);
1H NMR
(400 MHz, CDCl3): d=1.23 (t, J=7.2 Hz, 1.8H, keto CH2CH3), 1.30 (t,
J=7.2 Hz, 1.2H, enol CH2CH3), 1.37–2.66 (m, 14H), 3.62 (m, 0.6H,
keto CHC=O), 4.14 (q, J=7.2 Hz, 1.2H, keto CH2CH3), 4.21 (q, J=
7.2 Hz, 0.8H, enol CH2CH3), and 12.76 ppm (s, 0.4H, ex. with D2O,
enol OH); MS (FAB




+ calcd for C12H21O3: 213.1491, found: 213.1499.
3-Hydroxy-8,9,10,11,12,13-hexahydrocyclonona[c]chromen-
6(7H)-one (6b). Resorcinol (1.56 g, 14.1 mmol) was first dissolved
in hot 6a(3.0 g, 14 mmol). Upon cooling to room temperature, the
resulting syrup at 08C was treated dropwise with a mixture of
CF3COOH (2.2 mL, 28 mmol) and concd H2SO4 (1.5 mL, 28 mmol)
while keeping the reaction temperature <108C. After stirring for
3 h at room temperature, the orange gluey mass was cautiously
quenched with ice-water. The orange precipitate that formed was
collected by suction filtration, washed exhaustively with water and
air dried. A solution of the precipitate in a minimal volume of ace-
tone was fractionated by flash chromatography (CHCl3/acetone,
8:1 ! 4:1 gradient). The main fraction collected gave a white solid
which was recrystallised from THF/hexane to give 6b as white fine
crystals (909 mg, 25%): Rf=0.82 (CHCl3/acetone, 3:1); mp: 197–
2008C;
1H NMR (400 MHz, CDCl3): d=1.29–2.51 (m, 10H, 5 CH2),
2.66 (t, J=5.8 Hz, 2H, C7-CH2), 2.93 (t, J=6.1 Hz, 2H, C13-CH2), 6.69
(d, J=2.4 Hz, 1H, C4-H), 6.78 (dd, J=2.4 and 8.8 Hz, 1H, C2-H),
7.59 (d, J=8.8 Hz, 1H, C1-H) and 10.39 ppm (s, 1H, OH); MS
(FAB
+): m/z (%): 259.1 (100) [M+H]
+;M S( F A B




+ calcd for C16H19O3:
259.1334, found: 259.1323; Anal. calcd for C16H18O3: C 74.40, H
7.02, found: C 74.10, H 6.91; HPLC: Waters Radialpak column (RP18,
8 100 mm), MeOH/H2O (70:30), flow rate=2 mLmin
 1, lmax=
323.2 nm, tR=6.5 min, purity >98%.
6-Oxo-6,7,8,9,10,11,12,13-octahydrocyclonona[c]chromen-3-yl
sulfamate (6). NaH (60% dispersion in mineral oil, 1 equiv) was
added to a solution of 6b (400 mg, 1.55 mmol) in anhydrous DMF
(20 mL) at 08C under N2. When the evolution of H2 had ceased, sul-
famoyl chloride (~0.69m in toluene,
[19] ~3–5 equiv, evaporated
down to ~1 mL prior to addition) was introduced in one portion.
After stirring at room temperature under N2 overnight, the reaction
mixture was quenched with ice-water. Upon addition of EtOAc
(~100 mL), the organic fractions were washed with brine (4 
100 mL). After drying (MgSO4), filtering and evaporating the
washed organic layer, a crude white solid was obtained which was
purified by flash chromatography (CHCl3/EtOAc, 8:1 ! 2:1 gradi-
ent). The main fraction isolated gave a white solid which was re-
crystallised from THF/hexane to give 6 as fine white crystals
(201 mg, 38%): Rf=0.46 (CHCl3/EtOAc, 4:1); mp: 167–1688C;
1H NMR (400 MHz, CDCl3): d=0.84–1.74 (m, 10H, 5 CH2), 1.52 (t,
J=5.8 Hz, 2H, C7-CH2), 1.57 (t, J=6.1 Hz, 2H, C13-CH2), 7.26 (dd,
J=2.4 and 8.8 Hz, 1H, C2-H), 7.31 (d, J=2.1 Hz, 1H, C4-H), 7.89 (d,
J=8.8 Hz, 1H, C1-H) and 8.20 ppm (s, 2H, NH2); MS (FAB
+): m/z
(%): 338.0 (100) [M+H]
+;M S( F A B
 ): m/z (%): 336.1 (100) [M H]
 ,




C16H20NO5S: 338.1062, found: 338.1061; Anal. calcd for C16H19NO5S:
C 56.96, H 5.68, N 4.15, found: C 56.85, H 5.58, N 4.00; HPLC:
Waters Radialpak column (RP18, 8 100 mm), MeOH/H2O (70:30),
flow rate=2 mLmin
 1, lmax=284 and 312.5 nm, tR=3.1 min, purity
>98%.
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Irosustat SAREthyl 2-oxocyclodecanecarboxylate (7a). Prepared in a similar
manner to 6a using NaH (1.3 g, 32 mmol), diethyl carbonate
(60 mL), and cyclodecanone (2.5 g, 16 mmol). The crude pale-
yellow oily residue was purified by distillation under reduced pres-
sure to give 7a as a colourless oil (2.81 g, 76%): Rf=0.81 (CHCl3);
bp0.23: 84–878C (Lit. [34] bp1: 118–1208C);
1H NMR (400 MHz,
CDCl3): d=1.24 (t, J=7.0 Hz, 1.2H, keto CH2CH3), 1.31 (t, J=7.0 Hz,
1.8H, enol CH2CH3), 1.34–2.76 (m, 16H), 3.82–3.85 (m, 0.7H, keto
CHC=O), 4.13 (q, J=7.0 Hz, 0.5H, keto CH2CH3), 4.22 (q, J=7.0 Hz,
1.5H, enol CH2CH3) and 12.98 ppm (s, 0.3H, ex. with D2O, enol OH);
MS (FAB




+ calcd for C13H23O3: 227.1647, found: 227.1644.
3-Hydroxy-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chro-
men-6-one (7b). Prepared in a similar manner to 6busing resorci-
nol (970 mg, 8.84 mmol), 7a (2.0 g, 8.8 mmol), and a mixture of
CF3COOH (1.5 mL, 18 mmol) and concd H2SO4 (1.0 mL, 18 mmol).
The crude dark-orange solid was purified by flash chromatography
(CHCl3/acetone, 8:1 ! 4:1 gradient), and the white solid that was
isolated was recrystallised from THF/hexane to give 7b as white
crystals (789 mg, 33%): Rf:=0.72 (CHCl3/acetone, 3:1); mp: 240–
2418C;
1H NMR (400 MHz,[ D 6]DMSO): d=0.88–2.18 (m, 12H, 6 
CH2), 2.83 (t, J=6.7 Hz, 2H, C7-CH2), 3.02 (t, J=6.7 Hz, 2H, C14-
CH2), 5.96 (s, 1H, OH), 6.78 (dd, J=2.7 and 8.5 Hz, 1H, C2-H), 6.83
(d, J=2.7 Hz, 1H, C4-H) and 7.53 ppm (d, J=8.5 Hz, 1H, C1-H); MS
(FAB
+) m/z (%): 273.1 (100) [M+H]
+;M S( F A B




+ calcd for C17H21O3:
273.1491, found: 273.1488; Anal. calcd for C17H20O3: C 74.94, H
7.40, found: C 74.30, H 7.43; HPLC: Waters Radialpak column,
MeOH/H2O (80:20), flow rate=2 mLmin
 1, lmax=322 nm, tR=
4.5 min, purity >95%.
6-Oxo-7,8,9,10,11,12,13,14-octahydro-6H-cyclodeca[c]chromen-3-
yl sulfamate (7). Compound 7b (400 mg, 1.47 mmol) was sulfa-
moylated in a similar manner to 6b and the crude white solid ob-
tained was purified by flash chromatography (CHCl3/EtOAc, 8:1 !
2:1 gradient). The white solid that was isolated was recrystallised
from THF/hexane to give 7 as fine white crystals (235 mg, 46%):
Rf=0.71 (CHCl3/EtOAc, 4:1); mp: 183–1858C;
1H NMR (400 MHz,
[D6]DMSO): d=1.17–3.0 (m, 14H, 7 CH2), 3.09 (t, J=6.4 Hz, 2H,
C14-CH2), 7.26 (m, 1H, C2-CH), 7.46 (d, J=1.2 Hz, 1H, C4-H), 7.93
(d, J=8.8 Hz, 1H, C1-H) and 8.21 ppm (s, 2H, NH2); MS (FAB
+): m/z
(%): 352.0 (100) [M+H]
+;M S( F A B
 ): m/z (%): 350.1 (100) [M H]
 ,




C17H22NO5S: 352.1219, found: 352.1223; Anal. calcd for C17H21NO5S:
C 58.10, H 6.02, N 3.99%, found: C 58.40, H 6.28, N, 2.63; HPLC:
Waters Radialpak column, MeOH/H2O (70:30), flow rate=
2 mLmin
 1, lmax=284 and 312.5 nm, tR=6.3 min, purity >98%.
Ethyl 2-oxocycloundecanecarboxylate (8a). Prepared in a similar
manner to 6a using NaH (1.19 g, 29.7 mmol), diethyl carbonate
(70 mL), and cycloundecanone (2.5 g, 15 mmol). The crude yellow
oily residue was purified by distillation under reduced pressure to
give 6a as a pale-yellow oil (2.07 g, 58%): Rf=0.31 (CH2Cl2); bp0.15:
103–1088C (Lit. [34] bp5: 140–1438C);
1H NMR (400 MHz, CDCl3)
d=1.20 (t, J=7.0 Hz, 3H, CH2CH3), 1.26–2.76 (m, 19H) and
4.10 ppm (q, J=7.3 Hz, 2H, CH3CH2); MS (FAB
+): m/z (%): 241.1
(100) [M+H]
+;M S( F A B




+ calcd for C14H25O3: 241.1804, found: 241.1806.
3-Hydroxy-8,9,10,11,12,13,14,15-octahydrocycloundeca[c]chro-
men-6(7H)-one (8b). Prepared in a similar manner to 6b using re-
sorcinol (917 mg, 8.33 mmol), 8a (2.0 g, 8.3 mmol) and a mixture
of CF3COOH (2.0 mL, 17 mmol) and concd H2SO4 (1.6 mL,
17 mmol). The crude yellow solid was purified by flash chromatog-
raphy (CHCl3/acetone, 8:1 ! 4:1 gradient) and the yellow solid
that was isolated was recrystallised from THF/hexane to give 8bas
fine pale-yellow crystals (344 mg, 14%): Rf=0.76 (CHCl3/acetone,
3:1); mp: 214–2158C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.26–1.68
(m, 14H, 7 CH2), 2.56 (t, J=7.0 Hz, 2H, C7-CH2), 2.84 (t, J=7.0 Hz,
2H, C15-CH2), 6.67 (d, J=2.1 Hz, 1H, C4-H), 6.78 (dd, J=2.1 and
8.7 Hz, 1H, C2-H), 7.63 (d, J=8.8 Hz, 1H, C1-H) and 10.42 ppm (s,
1H, OH); MS (FAB
+): m/z (%) 287.1 (100) [M+H]
+;M S( F A B
 ): m/z




C18H23O3: 287.1647, found: 287.1644; Anal. calcd for C18H22O3:C
75.50, H 7.74, found: C 75.50, H 7.75; HPLC: Waters Radialpak
column, MeOH/H2O (80:20), flow rate=2 mLmin
 1, lmax=
323.2 nm, tR=6.5 min, purity >98%.
6-Oxo-6,7,8,9,10,11,12,13,14,15-decahydrocycloundeca[c]chro-
men-3-yl sulfamate (8). Compound 8b (300 mg, 1.05 mmol) was
sulfamoylated in a similar manner to 6b and the crude white solid
obtained was purified by flash chromatography (CHCl3/EtOAc, 8:1
! 2:1 gradient). The white solid that was isolated was recrystal-
lised from THF/hexane to give 8 as fine white crystals (133 mg,
35%): Rf=0.37 (CHCl3/EtOAc, 4:1); mp: 145–1488C;
1H NMR
(400 MHz,[ D 6]DMSO): d=1.28–1.76 (m, 14H, 7 CH2), 2.64 (t, J=
7.0 Hz, 2H, C7-CH2), 2.93 (t, J=7.0 Hz, 2H, C15-CH2), 7.26 (dd, J=
2.1 and 8.8 Hz, 1H, C2-H), 7.29 (d, J=2.1 Hz, 1H, C4-H), 7.93 (d, J=
8.8 Hz, 1H, C1-H) and 8.20 ppm (s, 2H, NH2); MS (FAB
+): m/z (%)
731.2 (10) [2M+H]
+, 366.0 (100) [M+H]
+;M S( F A B
 ): m/z (%):
364.1 (100) [M H]




+ calcd for C18H24NO5S: 366.1375, found: 366.1368; Anal.
calcd for C18H23NO5S: C 59.16, H 6.34, found: C 59.20, H 6.57; HPLC:
Waters Radialpak column, MeOH/H2O (80:20), flow rate=
2 mLmin
 1, lmax=285.2 and 312.5 nm, tR=3.8 min, purity >98%.
Ethyl 2-oxocyclododecanecarboxylate (9a). Prepared in a similar
manner to 6a using NaH (2.19 g, 54.9 mmol), diethyl carbonate
(100 mL) and cyclododecanone (5.0 g, 27 mmol). The crude dark-
yellow oily residue was purified by distillation under reduced pres-
sure to give 9aas a pale-yellow oil (5.62 g, 81%): Rf=0.72 (CH2Cl2);
bp0.23: 128–1328C (Lit. [34] bp3: 155–1578C);
1H NMR (400 MHz,
CDCl3): d=1.25 (t, J=7.0 Hz, 3H, CH2CH3), 1.29–2.73 (m, 21H) and
4.16 ppm (q, J=6.4 Hz, 2H, CH3CH2); MS (FAB
+): m/z (%): 255.1
(100) [M+H]
+;M S( F A B




+ calcd for C15H27O3: 255.1960, found: 255.1968.
3-Hydroxy-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclodode-
ca[c]chromen-6-one (9b). Prepared in a similar manner to 6b
using resorcinol (1.08 g, 9.8 mmol), 9a (2.5 g, 9.8 mmol) and a mix-
ture of CF3COOH (1.5 mL, 20 mmol) and concd H2SO4 (1.0 mL,
20 mmol). The crude pale-yellow solid was purified by flash chro-
matography (CHCl3/acetone, 8:1 ! 4:1 gradient) and the pale-
yellow solid that was isolated was recrystallised from THF/hexane
to give 9b as white crystals (972 mg, 33%): Rf=0.76 (CHCl3/ace-
tone, 3:1); mp: 249–2518C;
1H NMR (400 MHz,[ D 6]DMSO): d=
1.39–2.89 (m, 16H, 8 CH2), 2.93 (t, J=7.3 Hz, 2H, C7-CH2), 3.22 (t,
J=7.3 Hz, 2H, C16-CH2), 6.66 (d, J=2.3 Hz, 1H, C4-H), 6.78 (dd, J=
2.3 and 8.9 Hz, 1H, C2-H), 7.63 (d, J=8.9 Hz, 1H, C1-H) and
10.77 ppm (s, 1H, OH); MS (FAB
+): m/z (%): 301.1 (100) [M+H]
+;
MS (FAB




calcd for C19H25O3: 301.1804, found: 301.1806; Anal. calcd for
C19H24O3: C 75.97, H 8.05, found: C 75.90, H 8.03; HPLC: Waters Ra-
dialpak column, MeOH/H2O (90:10), flow rate=2 mLmin
 1, lmax=
324.4 nm, tR=4.2 min, purity >98%.
6-Oxo-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclododeca[c]-
chromen-3-yl sulfamate (9). Compound 9b (400 mg, 1.33 mmol)
was sulfamoylated in a similar manner to 6b and the crude white
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8:1 ! 2:1 gradient). The white solid that was isolated was recrys-
tallised from THF/hexane to give 9 as fine white crystals (182 mg,
36%): Rf=0.47 (CHCl3/EtOAc, 4:1); mp: 173–1758C;
1H NMR
(400 MHz,[ D 6]DMSO): d=1.41–2.51 (m, 16H, 8 CH2), 2.62 (t, J=
7.3 Hz, 2H, C7-CH2), 3.68 (t, J=7.6 Hz, 2H, C16-CH2), 7.26 (dd, J=
2.4 and 8.5 Hz, 1H, C2-H), 7.28 (d, J=2.4 Hz, 1H, C4-H), 7.94 (d, J=
8.5 Hz, 1H, C1-H) and 8.20 ppm (s, 2H, NH2); MS (FAB
+): m/z (%):
380.1 (100) [M+H]
+, 301.1 (15) [M+H HNSO2]
+;M S( F A B
 ): m/z
(%): 378.1 (100) [M H]




+ calcd for C19H26NO5S: 380.1532, found: 380.1541; Anal.
calcd for C19H25NO5S: C 60.14, H 6.64, N 3.69, found C 60.30, H 6.85,
N 3.62; HPLC: Waters Radialpak column, MeOH/H2O (90:10), flow
rate=2 mLmin
 1, lmax=285.2 and 312.5 nm, tR=5.3 min, purity
>98%.
Ethyl 2-oxocyclotridecanecarboxylate (10a). Cyclic b-keto ester
10a was obtained commercially.
3-Hydroxy-8,9,10,11,12,13,14,15,16,17-decahydrocyclotrideca[c]-
chromen-6(7H)-one (10b). Prepared in a similar manner to 6b
using resorcinol (451 mg, 4.10 mmol), 10a (1.0 g, 3.73 mmol) and a
mixture of CF3COOH (0.64 mL, 8.20 mmol) and concd H2SO4
(0.83 mL, 8.20 mmol). The light-beige residue (1.14 g) that was ob-
tained was recrystallised from hot iPrOH to give 10b as soft yellow
crystals (300 mg, 25.6%): Rf=0.51 (CHCl3/EtOAc, 4:1); mp: 234–
2388C;
1H NMR (400 MHz, CDCl3) d=1.1–1.8 (18H), 2.39 (m, 2H,
C7-CH2), 2.65 (m, 2H, C17-CH2), 6.70 (d, J=2.4 Hz, 1H, C4-H), 6.81
(dd, J=2.4 and 8.8 Hz, 1H, C2-H), 7.61 (d, J=8.8 Hz, 1H, C1-H) and
10.38 ppm (s, 1H, ex. with D2O, OH); MS (FAB
+): m/z (%): 315.3
(100) [M+H]
+;M S( F A B





+ calcd for C20H27O3:
315.1960, found: 315.1975; Anal. calcd for C20H26O3: C 76.39, H
8.34, found: C 76.1, H 8.41. The mother liquor of the crystals ob-
tained above was fractionated by flash chromatography (CHCl3/
EtOAc, 8:1 ! 2:1 gradient) to yield another 150 mg of 10b as
white residue.
6-Oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclotride-
ca[c]chromen-3-yl sulfamate (10). Compound 10b (370 mg,
1.18 mmol) was sulfamoylated in a similar manner to 6b and the
crude light-yellow residue obtained (407 mg) on dissolving in a
minimal volume of acetone was fractionated by flash chromatogra-
phy (CHCl3/acetone, 12:1 ! 2:1 gradient). The second fraction that
was isolated gave a white residue (140 mg, 20%) which was recrys-
tallised from THF/hexane to give 10 as white crystals (74 mg): Rf=
0.34 (CHCl3/acetone, 8:1); mp: 170–1748C;
1H NMR (400 MHz,
[D6]DMSO): d=1.2–1.7 (18H), 2.47 (m, 2H, C17-CH2), 7.26 (dd, J=
2.3 and 8.7 Hz, 1H, C2-H), 7.30 (d, J=2.3 Hz, 1H, C4-H), 7.92 (d, J=
8.7 Hz, 1H, C1-H) and 8.20 ppm (s, 2H, ex. with D2O, NH2); MS
(FAB
+): m/z (%): 787.1 (6) [2M+H]
+, 394.0 (100) [M+H]
+;M S
(FAB
 ): m/z (%): 785.2 (12) [2M H]





+ calcd for C22H28NO5S:
394.1668, found, 394.1712; Anal. calcd for C20H27NO5S: C 61.04, H
6.92, N 3.56, found C 61.4, H 7.22, N 3.27.
Ethyl 2-oxocyclopentadecanecarboxylate (11a). Prepared in a
similar manner to 6a using NaH (891 mg, 22.3 mmol), diethyl car-
bonate (70 mL) and cyclopentadecanone (2.5 g, 11.2 mmol). The
crude yellow syrup obtained was purified by flash chromatography
(CH2Cl2) to give 11a as a pale-yellow oil (1.62 g, 49%): Rf=0.70
(CH2Cl2);
1H NMR (400 MHz, CDCl3): d=1.64 (t, J=6.7 Hz, 3H,
CH2CH3), 1.15–1.62 (m, 25H), 2.55 (t, J=7.0 Hz, 2H, ring C2-CH2)
and 4.16 ppm (q, J=7.3 Hz, 2H, CH2CH3); MS (FAB
+): m/z (%): 297.2
(100) [M+H]
+;M S( F A B




+ calcd for C18H33O3: 297.2429, found: 297.2430.
3-Hydroxy-8,9,10,11,12,13,14,15,16,17,18,19-dodecahydrocyclo-
pentadeca[c]chromen-6(7H)-one (11b). Prepared in a similar
manner to 6b using resorcinol (558 mg, 5.06 mmol), 11a (1.5 g,
5.1 mmol) and a mixture of CF3COOH (1.0 mL, 10 mmol) and concd
H2SO4 (1.0 mL, 10 mmol). The crude brown solid obtained was puri-
fied by flash chromatography (CHCl3/acetone, 8:1 ! 4:1 gradient)
and the yellow solid that was isolated was recrystallised from THF/
hexane to give 11b as pale-yellow crystals (432 mg, 25%): Rf=0.69
(CHCl3/acetone, 3:1); mp: 209–2118C;
1H NMR (400 MHz, CDCl3):
d=1.25–1.62 (m, 22H, 11 CH2), 2.57 (t, J=7.8 Hz, 2H, C7-CH2),
2.74 (t, J=7.0 Hz, 2H, C19-CH2), 6.04 (s, 1H, OH), 6.81 (dd, J=2.7
and 8.9 Hz, 1H, C2-H), 6.92 (d, J=2.7 Hz, 1H, C4-H) and 7.45 ppm
(d, J=8.9 Hz, 1H, C1-H); MS (FAB
+): m/z (%): 343.1 (100) [M+H]
+;
MS (FAB




calcd for C22H31O3: 343.2273, found: 343.2269; Anal. calcd for
C22H30O3: C 77.16, H, 8.83, found C 77.12, H 8.89; HPLC: Waters Ra-
dialpak column, MeOH/H2O (90:10), flow rate=2 mLmin
 1, lmax=
324.4 nm, tR=8.5 min, purity >98%.
6-Oxo-6,7,8,9,10,11,12,13,14,15,16,17,18,19-tetradecahydrocyclo-
pentadeca[c]chromen-3-yl sulfamate (11). Compound 11b
(350 mg, 1.02 mmol) was sulfamoylated in a similar manner to 6b
and the crude white solid obtained was purified by flash chroma-
tography (CHCl3/EtOAc, 8:1 ! 2:1 gradient) to give a thick waxy
solid that was difficult to recrystallise. Further purification by prep-
arative TLC (CHCl3/EtOAc, 4:1) gave a white solid (201 mg), that
was recrystallised from THF/hexane to give 11 as fine white flakes
(185 mg, 43%): Rf=0.50 (CHCl3/EtOAc, 4:1); mp: 163–1668C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.32–1.59 (m, 22H, 11 CH2),
2.51–2.81 (m, 4H, C7-CH2 and C19-CH2), 7.26–7.28 (m, 2H, C2-H
and C4-H), 7.89 (d, J=7.8 Hz, 1H, C1-H) and 8.19 ppm (s, 2H, NH2);
MS (FAB
+): m/z (%): 842.3 (70) [2M+H]
+, 422.1 (100) [M+H]
+;M S
(FAB
 ): m/z (%): 841.4 (80) [2M H]





+ calcd for C22H32NO5S:
422.1999, found: 422.1994; Anal. calcd for C22H31NO5S: C 62.68, H
7.41, N 3.32, found: C 62.80, H 7.56, N 3.00; HPLC: Waters Radialpak
column, MeOH/H2O (90:10), flow rate=2 mLmin
 1, lmax=285.2
and 313.7 nm, tR=4.2 min, purity >98%.
6-Oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl dime-
thylsulfamate (12). N,N-Dimethylsulfonyl chloride (1.90 mL,
17.55 mmol) was added dropwise to a mixture of 3-hydroxy-
8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one (2.0 g,
8.69 mmol)
[17] in N,N-dimethylcyclohexylamine (10 mL). The result-
ing mixture was heated at 908C for 1 h. The brown slurry obtained
was cooled to room temperature and diluted with EtOAc (150 mL).
The organic fraction was then washed sequentially with NaOH
(1m, 2 100 mL), HCl (2m, 2 100 mL) and brine (3 50 mL); it was
dried (MgSO4) and evaporated to give a light-yellow residue
(2.94 g). Recrystallisation from hot EtOAc/hexane (2.5:1) gave 12 as
a light-yellow crystalline solid (2.0 g, 5.93 mmol, 68%): mp: 159–
160.58C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.52 (m, 2H), 1.61 (m,
2H), 1.86 (m, 2H), 2.81 (m, 2H), 2.94 (s, 6H, 2 N-CH3), 3.00 (m, 2H,
C11-H2), 7.32 (dd, J=2 and 8.9 Hz, 1H, C2-H), 7.39 (d, J=2.73 Hz,
1H, C4-H) and 8.01 ppm (d, J=8.9 Hz, 1H, C1-H); MS (AP
+): m/z
(%): 338.2 (100) [M+H]
+; Anal. calcd for C16H19NO5S: C 56.96, H
5.68, N, 4.15, found: C 57.0, H 5.71, N 4.32.
4-Methoxybenzene-1,3-diol (13a). Starting material 13a was pre-
pared according to the method of Godfrey et al.
[20]
3-Hydroxy-2-methoxy-8,9,10,11-tetrahydrocyclohepta[c]chro-
men-6(7H)-one (13b). A mixture of 13a (1.05 g, 7.49 mmol) and
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Irosustat SARmethyl 2-oxo-1-cycloheptane carboxylate (1.35 g, 7.87 mmol) at
08C was treated dropwise with a mixture of CF3COOH (1.2 mL,
15 mmol) and concd H2SO4 (1.5 mL, 15 mmol) while keeping the
reaction temperature <108C. After stirring for 3 h at room temper-
ature, the dark-brown mixture was cautiously quenched with ice-
water followed by the addition of EtOAc (200 mL). The organic
layer that separated was washed with H2O (4 100 mL) and dried
by azeotropic evaporation with iPrOH. The dark-purple residue ob-
tained (2.0 g) was recrystallised from hot EtOAc and hexane to give
13b as pink crystals (1.23 g, 25%): mp: 158–1598C. Upon fractiona-
tion of the residue retrieved from the mother liquor by flash chro-
matography (EtOAc/hexane, 1:4 ! 4:1 gradient), the second frac-
tion that was isolated gave a yellow residue (321 mg) that was re-
crystallised from hot EtOAc and hexane to give a second crop of
13b (184 mg, total 72%) as creamy crystals: Rf=0.46 (EtOAc/
hexane, 2:1); mp: 158–1598C;
1H NMR (400 MHz,[ D 6]DMSO): d=
1.49 (m, 2H), 1.60 (m, 2H), 1.83 (m, 2H), 2.76 (m, 2H, C7-H2), 2.96
(m, 2H, C11-CH2), 3.86 (s, 3H, OCH3), 6.76 (s, 1H, C4-H), 7.25 (s, 1H,
C1-H) and 10.15 ppm (brs, 1H, ex. with D2O, OH); MS (FAB
+): m/z
(%) 259.1 (100) [M+H]
+;M S( F A B




+ calcd for C16H19O3: 259.1334, found:
259.1323; Anal. calcd for C15H16O4: C 69.20, H 6.20, found: C 69.1, H
6.16.
2-Methoxy-6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-
3-yl sulfamate (13). Compound 13b (500 mg, 1.92 mmol) in anhy-
drous DMF (10 mL) was sulfamoylated in a similar manner to 6b.
The crude pale-yellow residue obtained was purified by flash chro-
matography (CHCl3/THF, 16:1 ! 2:1 gradient). The second fraction
isolated gave a white solid that was recrystallised from THF/hexane
to give 13 as a white powder (204 mg, 31%): mp: 193–1958C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.52 (m, 2H), 1.62 (m, 2H), 1.86
(m, 2H), 2.83 (m, 2H, C7-H2), 3.04 (m, 2H, C11-CH2), 3.91 (s, 3H,
OCH3), 7.37 (s, 1H, C4-H), 7.48 (s, 1H, C1-H) and 8.17 ppm (s, 2H,
ex. with D2O, OSO2NH2); MS (ES
+) m/z (%): 340.0 (100) [M+H]
+;
Anal. calcd for C15H17NO6S: C 53.09, H 5.05, N 4.13, found C 53.1, H
5.06, N 4.01; HPLC: Sunfire C18 reversed-phase column, 4.6 
75 mm, 3.5 mm pore size, MeOH/H2O (80:20), flow rate=
0.8 mLmin
 1, tR=2.12 min, purity >98%.
2-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one
(14a). Hydroquinone (3.56 g, 32.34 mmol) was dissolved in hot
methyl 2-oxo-1-cycloheptanecarboxylate (5.0 g, 4.59 mL,
29.4 mmol). To this stirred brown suspension at ice-water tempera-
ture was added dropwise a mixture of CF3COOH (5.0 mL,
64.68 mmol) and concd H2SO4 (6.47 mL, 64.68 mmol) at such a rate
that the reaction temperature was kept <108C( ~30 min). The re-
action mixture was then allowed to warm to room temperature
and thereupon stirred for an additional 60 h before being
quenched cautiously with ice-water. After stirring the suspension
that formed for 1 h, the pale-cream precipitate was collected by
suction filtration, washed exhaustively with H2O and air dried. The
crude product was purified by recrystallisation from acetone to
give 14a as colourless needles (0.19 g, 3%): mp: 204–2068C;
1H NMR (270 MHz,[ D 6]DMSO): d=1.49 (m, 2H), 1.69 (m, 2H), 1.79
(m, 2H), 2.68 (m, 2H), 2.83 (m, 2H), 7.16 (dd, J=2.95 and 8.9 Hz,
1H), 7.30 (d, J=2.9 Hz, 1H), 7.43 (d, J=8.9 Hz, 1H), 9.88 ppm (s,
1H, ex. with D2O);
13C NMR (100 MHz,[ D 6]DMSO): d=21.65 (CH2),
24.48 (CH2), 26.11 (CH2), 31.29 (CH2), 34.01 (CH2), 107.80 (CH),
119.32 (CH), 120.82, 122.41 (CH), 123.08, 148.92, 154.30, 168.69,
175.45 ppm; MS (FAB




+ calcd for C14H15O3: 231.10212, found 231.10255; Anal.
calcd for C14H15O3: C 73.0, H 6.13, found: C 73.0, H 6.15.
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-2-yl sulfa-
mate (14). To an ice-cooled solution of 14a (100 mg, 0.43 mmol) in
anhydrous DMA (5 mL) was added sulfamoyl chloride (0.7m solu-
tion in toluene, 3.04 mL; the toluene was removed in vacuo [not
allowing the temperature of the water bath to exceed 308C] prior
to addition, 4.34 mmol) and the mixture stirred (under a positive
flow of dry N2) overnight. The mixture was diluted with EtOAc
(25 mL), washed with H2O (3 50 mL) and brine (50 mL) and con-
centrated in vacuo (not allowing the temperature of the water
bath to exceed 308C). The product was precipitated with Et2O/
n-hexane, washed with n-hexane, and vacuum dried to give 14 as
an off-white amorphous powder (70 mg, 52%): mp: 185–1878C
(dec);
1H NMR (400 MHz,[ D 6]DMSO): d=1.50 (m, 2H), 1.69 (m,
2H), 1.81 (m, 2H), 2.70 (m, 2H), 2.88 (m, 2H), 7.59 (dd, J=3.2 and
8.97 Hz, 1H), 7.68 (d, J=8.97 Hz, 1H), 7.86 (d, J=3.2 Hz, 1H),
8.08 ppm (s, 2H, ex. with D2O);
13C NMR (100 MHz,[ D 6]DMSO): d=
22.49 (CH2), 25.29 (CH2), 26.79 (CH2), 32.05 (CH2), 34.81 (CH2),
118.54, 120.79, 122.58 (CH), 123.39 (CH), 128.90 (CH), 147.27,
153.73, 170.07, 175.55 ppm; MS (FAB




+ calcd for C14H16NSO5: 310.0749,
found: 310.0753; Anal. calcd for C14H16NSO5: C 54.4, H 4.89, N 4.53,
found: C 54.0, H 5.01, N 4.31; purity of sample (as calculated by
1H NMR): 97.4%
3-Hydroxy-8,9,10,11-tetrahydro-5H-cyclohepta[c]quinolin-6(7H)-
one (16a). A slurry of 3-aminophenol (2.0 g, 18.33 mmol) in methyl
2-oxo-1-cycloheptane carboxylate (3.12 g, 18.33 mmol) was heated
at 1508C for 8 h. After cooling, EtOAc (50 mL) was added to the
crude dark-brown residue and the resulting suspension was tritu-
rated in an ultrasonic bath for 30 min followed by filtration. The
precipitate that collected was washed with more EtOAc and air
dried to give 16a as pink/light-brown residue (3.05 g, 13.30 mmol,
73%): mp: 290–3008C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.44 (m,
2H), 1.55 (m, 2H), 1.81 (m, 2H), 2.81 (m, 2H, C7-H2), 2.93 (m, 2H,
C11-H2), 6.62 (dd, J=2.1 and 8.7 Hz, 1H, C2-H), 6.69 (d, J=2.1 Hz,
1H, C4-H), 7.64 (d, J=8.7 Hz, 1H, C1-H), 10.1 (s, 1H, ex. with D2O,
OH) and 11.4 ppm (1H, s, ex. with D2O, NH); MS (FAB
+) m/z (%)
230.3 (100) [M+H]
+;M S( F A B
 ) m/z (%) 382.3 (45) [M+NBA]
 ,
228.3 (100) [M H]
 ; HRMS-FAB
+: m/z [M+H]
+ calcd for C14H16NO2:
230.1181, found: 230.1184. This crude product was used for the
next reaction without further purification.
6-Oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-yl sul-
famate (16). NaH (60% in mineral oil, 53 mg, 1.31 mmol) was
added to a solution of 16a (300 mg, 1.30 mmol) in anhydrous DMF
(5 mL) at 08C, followed by a concentrated solution of sulfamoyl
chloride (~0.69m in toluene, ~5 equiv) in one portion 15 min later
after the evolution of H2 had ceased. The reaction mixture was
stirred at room temperature under an atmosphere of N2 overnight
before diluting with EtOAc (100 mL). The resulting mixture was
washed with brine (4 50 mL), dried (MgSO4) and concentrated in
vacuo to give an off-white residue that was fractionated on silica
with EtOAc. The first fraction that was collected gave an off-white
syrup (284 mg), which upon crystallisation from EtOAc/hexane
(5:1) gave 16 as white crystals (174 mg, 564 mmol, 43%): mp: 180–
1858C; IR (KBr) n ˜ =3420, 3300, 3200–3000, 2920, 2860, 1630, 1550,
1380, 1180 cm
 1;
1H NMR (270 MHz,[ D 6]DMSO): d=1.46 (m, 2H),
1.57 (m, 2H), 1.85 (m, 2H), 2.87 (m, 2H, C7-H2), 3.02 (m, 2H, C11-
H2), 7.08 (dd, J=2.4 and 9 Hz, 1H, C2-H), 7.23 (d, J=2.2 Hz, 1H,
C4-H), 7.94 (d, J=8.8 Hz, 1H, C1-H), 8.10 (s, 2H, ex. with D2O,
OSO2NH2) and 11.8 ppm (s, 1H, ex. with D2O, NH); MS (FAB
+): m/z
(%): 309.2 (100) [M+H]




+ calcd for C14H17N2O4S: 309.0909, found: 309.0916;
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H 5.27, N 8.96.
3-(Benzyloxy)-8,9,10,11-tetrahydro-5H-cyclohepta[c]quinolin-
6(7H)-one (17). NaH (60% in mineral oil, 350 mg, 8.75 mmol) was
added to a solution of 16a (2.0 g, 8.72 mmol) in DMF (100 mL) at
08C, followed by benzyl bromide (1.1 mL, 9.33 mmol) 15 min later
after the evolution of H2 had ceased. The reaction mixture was
heated at 908C for 30 min and then concentrated in vacuo after
cooling to room temperature. The light-beige sludge that was ob-
tained was diluted with EtOAc (200 mL) and filtered. The precipi-
tate that collected was washed with more EtOAc and H2O( 4  
50 mL) and air dried overnight to give 17 as a white powder (2.2 g,
6.89 mmol, 79%): Rf=0.69 (CHCl3/acetone, 1:2), c.f. Rf=0.58 (16a);
IR (KBr) n ˜ =3000–2800, 1650 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO):
d=1.42 (m, 2H), 1.53 (m, 2H), 1.81 (m, 2H), 2.80 (m, 2H), 2.94 (m,
2H), 5.11 (s, 2H, OCH2), 6.83 (dd, J=2.7 and 9 Hz, 1H, C2-H), 6.87
(d, J=2.7 Hz, 1H, C4-H), 7.38 (m, 5H, Ph), 7.73 (d, J=9 Hz, 2H, C1-
H) and 11.5 ppm (s, 1H, ex. with D2O, NH); MS (FAB
+): m/z (%):
320.0 (100) [M+H]
+, 229.0 (5) [M+H Bn]




+ calcd for C21H22NO2: 320.1651, found:
320.1661. This crude product was used for the next reaction with-
out further purification.
3-(Benzyloxy)-5-methyl-8,9,10,11-tetrahydro-5H-cyclohepta[c]-
quinolin-6(7H)-one (18a). NaH (60% in mineral oil, 65 mg,
1.63 mmol) was added to a solution of 17 (500 mg, 1.57 mmol) in
DMF (130 mL) at 08C, followed by CH3I (0.2 mL, 3.15 mmol) 15 min
later after the evolution of H2 had ceased. The reaction mixture
was heated at 808C for 50 min and then concentrated in vacuo
after cooling to room temperature. The beige residue obtained
was dissolved in EtOAc (150 mL), and the resulting mixture washed
with brine (3 50 mL), dried (MgSO4), filtered and evaporated to
give a yellow residue. This crude product was fractionated on silica
with CHCl3/EtOAc (8:1 ! 2:1 gradient). The second fraction that
was collected upon evaporation gave 18a as a white residue
(480 mg, 1.44 mmol, 92%). An analytical sample of this residue was
recrystallised from EtOAc/hexane (1:2) to give 18a as soft fine
needle-shaped crystals: mp: 119–1218C; Rf=0.78 (CHCl3/EtOAc,
1:2), c.f. Rf=0.58 (17); IR (KBr) n ˜ =2920, 2840, 1630, 1610, 1590,
1240 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO): d=1.45 (m, 2H), 1.56
(m, 2H), 1.83 (m, 2H), 2.90 (m, 2H), 2.98 (m, 2H), 3.61 (s, 3H,
NCH3), 5.26 (s, 2H, OCH2), 6.96 (dd, J=2.3 and 8.9 Hz, 1H, C2-H),
7.04 (d, J=2.7 Hz, 1H, C4-H), 7.43 (m, 5H, Ph) and 7.86 ppm (d, J=
8.9 Hz, 1H, C1-H);
13C NMR (100.4 MHz, CDCl3) d=26.01 (t), 26.54
(t), 26.91 (t), 28.64 (t), 30.68 (q, NCH3), 32.59 (t), 70.62 (t, OCH2),
100.36 (d), 109.93 (d), 115.12 (s), 126.02 (d), 127.65 (d), 128.38 (d),
128.87 (d), 130.77 (s), 136.55 (s), 140.45 (s), 148.84 (s), 159.86 (s)
and 162.57 ppm (s); MS (FAB
+): m/z (%): 334.3 (100) [M+H]
+,





calcd for C22H24NO2: 334.1807, found: 334.1798; Anal. calcd for
C22H23NO2: C 79.25, H 6.95, N 4.20, found: C 79.5, H 7.00, N 4.27.
3-Hydroxy-5-methyl-8,9,10,11-tetrahydro-5H-cyclohepta[c]quino-
lin-6(7H)-one (18b). Compound 18a (460 mg, 1.38 mmol) in THF
(15 mL) was added to a suspension of Pd/C (10%, 100 mg) in THF
(15 mL). The reaction mixture was stirred under an atmosphere of
H2 (balloon) at room temperature, and the progress of the reaction
was monitored by TLC. After the disappearance of the starting ma-
terial had completed, the suspension was filtered and the charcoal
retained washed with more THF. The combined filtrates were con-
centrated in vacuo, and the light-yellow residue obtained was re-
crystallised from hot THF/hexane (1:1) to give 18b as fine pale-
yellow crystals (148 mg, 608 mmol, 44%): Rf=0.37 (CHCl3/EtOAc,
1:2), c.f. Rf=0.63 (18a); mp: 255–2618C;
1H NMR (400 MHz,
[D6]DMSO): d=1.45 (m, 2H), 1.56 (m, 2H), 1.82 (m, 2H), 2.88 (m,
2H), 2.97 (m, 2H), 3.56 (s, 3H, NCH3), 6.73 (dd, J=2.3 and 9 Hz, 1H,
C2-H), 6.78 (d, J=2 Hz, 1H, C4-H), 7.76 (d, J=9 Hz, 1H, C1-H) and
10.11 ppm (brs, 1H, ex. with D2O, OH); MS (FAB
+): m/z (%): 244.2
(100) [M+H]
+;M S( F A B





+ calcd for C15H18NO2:
244.1338, found: 244.1333.
5-Methyl-6-oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quino-
lin-3-yl sulfamate (18). Compound 18b (100 mg, 411 mmol) in an-
hydrous DMF (5 mL) was sulfamoylated in a similar manner to 16a.
The crude pale-yellow syrup (130 mg) obtained was fractionated
on silica with EtOAc, and the first fraction that was collected gave
a pale-yellow syrup which upon crystallisation from hot EtOAc/
hexane (1:2) gave 18 as white crystals (45 mg, 140 mmol, 34%):
Rf=0.78 (EtOAc), c.f. Rf=0.68 (18b); mp: 185–1878C;
1H NMR
(400 MHz,[ D 6]DMSO): d=1.47 (m, 2H), 1.58 (m, 2H), 1.85 (m, 2H),
2.95 (m, 2H), 3.06 (m, 2H), 3.63 (s, 3H, NCH3), 7.19 (dd, J=2.2 and
9 Hz, 1H, C2-H), 7.37 (d, J=2.2 Hz, 1H, C4-H), 7.76 (d, J=9.2 Hz,
1H, C1-H) and 8.11 ppm (s, 2H, ex. with D2O, OSO2NH2); MS (FAB
+):
m/z (%): 323.1 (100) [M+H]
+, 243.1 (10) [M HNSO2]
+;M S( F A B
 ):
m/z (%): 321.1(100) [M H)




+ calcd for C15H19N2O4S: 323.1066, found: 323.1054;
Anal. calcd for C15H18N2O4S: C 55.89, H 5.63, N 8.69, found: C 55.8,
H 5.63, N, 8.63.
3-(Benzyloxy)-6-chloro-8,9,10,11-tetrahydro-7H-cyclohepta[c]qui-
noline (19a). A suspension of 17 (1.0 g, 3.13 mmol) in POCl3
(20 mL) was held at reflux for 2 h. After cooling to room tempera-
ture, ice-water and EtOAc (100 mL) were added to the dark-red/
brown reaction mixture. The organic layer that separated was
washed with H2O (4 50 mL), dried (MgSO4), filtered and concen-
trated in vacuo to give a light-yellow residue. This crude product
was recrystallised from hot iPrOH to give 19a as light-yellow crys-
tals (840 mg, 2.49 mmol, 79%): Rf=0.60 (EtOAc/hexane, 1:2), c.f.
Rf<0.05 (17); mp: 128.5–130.58C;
1H NMR (400 MHz,[ D 6]DMSO)
d=1.62 (m, 4H), 1.87 (m, 2H), 3.16 (m, 2H), 3.29 (m, 2H), 5.28 (s,
2H, OCH2), 7.41 (m, 7H) and 8.16 ppm (d, J=7.4 Hz, 1H); MS
(FAB
+): m/z (%) 338.3 (100) [M+H]
+, 91.1 (55); HRMS-FAB
+: m/z
[M+H]
+ calcd for C21H21NO
35Cl: 338.1312, found: 338.1308; Anal.
calcd for C21H20NOCl: C 74.66, H 5.97, N 4.15, found: C 74.5, H 5.94,
N 4.22.
3-(Benzyloxy)-6-methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]-
quinoline (19b). NaH (60% in mineral oil, 296 mg, 7.40 mmol) was
added to a mixture of anhydrous MeOH (240 mg, 7.49 mmol) and
anhydrous DMF (15 mL) at ice-water temperature. After stirring for
15 min, the resulting purple–grey mixture was then transferred
dropwise through a cannula to a solution of 19a (500 mg,
1.48 mmol) in anhydrous DMF (10 mL). The brown mixture/suspen-
sion that resulted was heated at 708C for 2 h, cooled, and diluted
with EtOAc (150 mL). The organic fraction was washed with brine
(5 100 mL), dried (MgSO4), filtered and concentrated in vacuo to
give a yellow–brown residue that was fractionated on silica with
EtOAc/hexane (1:8 ! 1:4 gradient). The first fraction that collected
upon evaporation gave 19b as a white residue (387 mg,
1.16 mmol, 78%): Rf=0.60 (EtOAc/hexane, 1:4), c.f. Rf=0.51 (19a);
1H NMR (400 MHz,[ D 6]DMSO) d=1.52 (m, 4H), 1.60 (m, 2H), 1.86
(m, 2H), 2.95 (m, 2H), 3.16 (m, 2H), 3.95 (s, 3H, OCH3), 5.25 (s, 2H,
OCH2), 7.11 (dd, J=2.6 and 9.2 Hz, 1H, C2-H), 7.24 (d, J=2.6 Hz,
1H, C4-H), 7.41 (m, 5H, Ph) and 7.99 ppm (d, J=9.2 Hz, 1H, C1-H);
MS (FAB
+): m/z (%): 334.3 (100) [M+H]
+, 91.1 (64); HRMS-FAB
+:
m/z [M+H]
+ calcd for C22H24NO2: 334.1807, found: 334.1801.
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Irosustat SAR6-Methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-ol
(19c). A solution of 19b (689 mg, 2.07 mmol) in absolute EtOH
(70 mL) was debenzylated by hydrogenation in a manner similar to
18a in the presence of Pd/C (10%, 70 mg). The crude light-yellow
residue that resulted (422 mg) was recrystallised from CHCl3/
hexane (5:6) to give 19c as white crystals (253 mg, 1.04 mmol,
50%): Rf=0.38 (CHCl3/EtOAc, 4:1), c.f. Rf=0.79 (19b); mp: unde-
fined but all melted by 1778C; IR (KBr) n ˜ =3600–2500, 2910, 2840,
1620, 1240 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO) d=1.51 (m, 2H),
1.58 (m, 2H), 1.85 (m, 2H), 2.92 (m, 2H), 3.12 (m, 2H), 3.93 (s, 3H,
OCH3), 6.92 (dd, J=2.5 and 9.2 Hz, 1H, C2-H), 7.00 (d, J=2.3 Hz,
1H, C4-H), 7.89 (d, J=9.3 Hz, 1H, C1-H) and 9.84 ppm (brs, 1H, ex.
with D2O, OH); MS (FAB
+) m/z (%) 244.3 (100) [M+H]
+;M S( F A B
 )
m/z (%) 395.4 (23) [M H+NBA]




+ calcd for C15H18NO2: 244.1338, found:
244.1333; Anal. calcd for C15H17NO2: C 74.05, H 7.04, N 5.76, found:
C 73.8, H 7.01, N 5.82.
6-Methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl
sulfamate (19). Sulfamoyl chloride (~5 equiv) was added to a solu-
tion of 19c (70 mg, 288 mmol) and 2,6-di-tert-butyl-4-methylpyri-
dine (60 mg, 292 mmol) in anhydrous CH2Cl2 (10 mL) at room tem-
perature. After stirring for 5 h under an atmosphere of N2, the reac-
tion mixture was concentrated in vacuo and the resulting yellow
syrup was dissolved in EtOAc (50 mL). The organic fraction was
washed with HCl (0.5m, 4 25 mL), H2O (2 50 mL), dried (MgSO4)
and concentrated in vacuo to give a light-brown residue (114 mg)
that upon recrystallisation from CHCl3/hexane (2:5) gave 19 as
white crystals (32 mg, 99.3 mmol, 34%): Rf=0.30 (EtOAc/hexane),
c.f. Rf=0.36 (19c); mp=94–978C; IR (KBr) n ˜ =3540, 3350, 3240,
2910, 2840, 1360, 1180, 1170 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO):
d=1.54 (m, 2H), 1.61 (m, 2H), 1.89 (m, 2H), 3.00 (m, 2H), 3.23 (m,
2H), 3.99 (s, 3H, OCH3), 7.31 (dd, J=2.3 and 9 Hz, 1H, C2-H), 7.63
(d, J=2.3 Hz, 1H, C4-H), 8.07 (brs, 2H, ex. with D2O, OSO2NH2) and
8.18 ppm (d, J=9 Hz, 1H, C1-H); MS (FAB
+): m/z (%): 323.3 (8) [M+
H]
+, 309.2 (100) [M+H CH2]
+, 230.2 (13) [M+H CH2 HNSO2]
+;
HRMS-FAB
+: m/z [M+H CH2]
+ calcd for C14H17N2O4S: 309.0909,
found: 309.0914; Anal. calcd for C15H18N2O4S: C 55.89, H 5.63, N
8.69, found: C 54.9, H 5.71, N 8.63.
3-(Benzyloxy)-5-pentyl-8,9,10,11-tetrahydro-5H-cyclohepta[c]qui-
nolin-6(7H)-one (20a) and 3-(benzyloxy)-6-(pentyloxy)-8,9,10,11-
tetrahydro-7H-cyclohepta[c]quinoline (21a). NaH (60% in mineral
oil, 65 mg, 1.62 mmol) was added to a solution of 17 (500 mg,
1.57 mmol) in DMF (40 mL) at room temperature cautiously fol-
lowed by 1-bromopentane (0.4 mL, 3.23 mmol) 15 min later after
the evolution of H2 had ceased. The reaction mixture was heated
at 1008C for 1 h and then concentrated in vacuo after cooling to
room temperature. The crude material that obtained was dissolved
in EtOAc (100 mL) and the resulting mixture was washed with
brine (4 50 mL), dried (MgSO4), filtered and evaporated to give a
yellow syrup which was fractionated on silica eluting first with
CHCl3/hexane (4:1), then CHCl3 followed by CHCl3/EtOAc (4:1 !
1:1 gradient). The first fraction that collected upon evaporation
gave 21a as a white residue (250 mg, 642 mmol, 41%): Rf=0.73
(CHCl3/hexane, 2:1), c.f. Rf<0.05 (17); IR (KBr) n ˜ =3000–2840, 1615,
1590, 1330 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO): d=0.90 (t, J=
7 Hz, 3H, CH3), 1.3–1.9 (m, 12H), 2.95 (m, 2H), 3.16 (m, 2H), 4.36 (t,
J=6.4 Hz, 2H, OCH2CH2), 5.24 (s, 2H, OCH2Ph), 7.09 (dd, J=2.7 and
8.9 Hz, 1H, C2-H), 7.20 (d, J=2.6 Hz, 1H, C4-H), 7.42 (m, 5H, Ph)
and 7.98 ppm (d, J=9.4 Hz, 1H, C1-H); MS (FAB+): m/z (%) 390.4
(95) [M+H]
+, 319.3 (23) [M+H C5H11]




+ calcd for C26H32NO2: 390.2433, found:
390.2440. The second fraction that collected upon evaporation
gave a light-yellow syrup (380 mg, 976 mmol, 62%) which was re-
crystallised from hexane (~50 mL) to give 20a as fine needle-
shaped white crystals (189 mg): Rf=0.62 (CHCl3), c.f. Rf<0.05 (17);
mp: 96–98.58C; IR (KBr) n ˜ =3000–2840, 1630, 1610, 1590,
1230 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO) d=0.87 (t, J=, 7 Hz, 3H,
CH3), 1.2–1.62 (m, 9H), 1.65 (m, 2H), 2.88 (m, 2H), 2.98 (m, 2H),
4.18 (t, J=7.4 Hz, 2H, NCH2), 5.29 (s, 2H, OCH2), 6.95 (m, 2H, C2-H
and C4-H), 7.40 (m, 5H, Ph) and 7.86 ppm (d, J=8.9 Hz, 1H, C1-H);
13C NMR (100.4 MHz, CDCl3): d=14.03 (q, CH3), 22.43 (t), 25.49 (t),
26.15 (t), 26.35 (t), 26.92 (t), 28.22 (t), 29.21 (t), 32.15 (t), 43.18 (t),
70.19 (t, OCH2), 99.94 (d), 109.40 (d), 109.53 (d), 114.88 (s), 125.67
(d), 127.03 (d), 127.93 (d), 128.48 (d), 130.45 (s), 136.26 (s), 139.18
(s), 148.09 (s), 159.33 (s) and 161.79 (s); MS (FAB
+): m/z (%): 390.4
(100) [M+H]





+ calcd for C26H32NO2: 390.2433, found: 390.2429; Anal.
calcd for C26H31NO2: C 80.17, H 8.02, N, 3.60, found: C 80.0, H 7.99,
N 3.57.
3-Hydroxy-5-pentyl-8,9,10,11-tetrahydro-5H-cyclohepta[c]quino-
lin-6(7H)-one (20b). A solution of 20a (405 mg, 1.04 mmol) in ab-
solute EtOH (30 mL) was debenzylated by hydrogenation in similar
manner to 18a in the presence of Pd/C (10%, 41 mg). The crude
white residue that resulted (235 mg, 785 mmol, 76%) was recrystal-
lised from CHCl3/hexane (3:2) to give 20b as white crystals
(253 mg, 1.04 mmol, 50%): Rf=0.52 (CHCl3/EtOAc, 8:1), c.f. Rf=0.84
(20a); mp: undefined but all melted by 1458C;
1H NMR (400 MHz,
[D6]DMSO): d=0.90 (t, J~7 Hz, 3H, CH3), 1.36 (m, 4H), 1.45 (m, 2H),
1.58 (m, 4H), 1.82 (m, 2H), 2.88 (m, 2H), 2.97 (m, 2H), 4.13 (t, J=
7.3 Hz, 2H, NCH2), 6.71 (dd, J=2 and 8.8 Hz, 1H, C2-H), 6.80 (d, J=
2.3 Hz, 1H, C4-H), 7.76 (d, J=9 Hz, 1H, C1-H), 8.32 (CHCl3, 0.5H)
and 10.1 ppm (brs, 1H, ex. with D2O, OH); MS (FAB
+): m/z (%):
300.3 (100) [M+H]
+, 229.2 (10) [M+H C5H11]
+;M S( F A B
 ): m/z
(%): 452.4 (40) [M+NBA]




+ calcd for C19H26NO2: 300.1964, found: 300.1955.
6-Oxo-5-pentyl-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quino-
lin-3-yl sulfamate (20). Compound 20b (178 mg, 595 mmol) in an-
hydrous DMF (10 mL) was sulfamoylated in a similar manner to
16a. The crude light-yellow residue (199 mg) that was obtained
was fractionated on silica with CHCl3/EtOAc (8:1). The fourth frac-
tion that was collected gave a creamy residue (125 mg, 330 mmol,
56%) which upon recrystallisation from hot CHCl3/hexane (1:2)
gave 20 as fine white crystals (97 mg): Rf=0.49 (CHCl3/EtOAc, 4:1),
c.f. Rf=0.67 (20b); mp: 186–1888C; IR (KBr) n ˜ =3650–3000, 3000–
2800, 1610, 1560, 1380 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO) d=
0.89 (t, J=7 Hz, 3H, CH3), 1.37 (m, 4H), 1.48 (m, 2H), 1.61 (m, 4H),
1.84 (m, 2H), 2.95 (m, 2H), 3.05 (m, 2H), 4.21 (t, J=7.7 Hz, 2H,
NCH2), 7.17 (dd, J=2.2 and 8.8 Hz, 1H, C2-H), 7.36 (d, J=2.2 Hz,
1H, C4-H), 8.05 (d, J=8.8 Hz, 1H, C1-H) and 8.10 ppm (s, 2H, ex.
with D2O, OSO2NH2); MS (FAB
+): m/z (%): 379.2 (100) [M+H]
+,
298.2 (27) [M H2NSO2]
+;M S( F A B
 ): m/z (%): 377.2 (100) [M H]
 ,




C19H27N2O4S: 379.1682, found: 379.1702. Anal. calcd for
C19H26N2O4S: C 60.30, H 6.92, N 7.40, found: C 60.1, H 6.92, N 7.43.
6-(Pentyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-ol
(21b). A solution of 21a (311 mg, 798 mmol) in absolute EtOH
(30 mL) was debenzylated by hydrogenation in similar manner to
18a in the presence of Pd/C (10%, 35 mg). The crude light-brown
syrup that was obtained was fractionated on silica with CHCl3 fol-
lowed by CHCl3/EtOAc (8:1 ! 4:1 gradient) to give 21b as a light-
brown syrup which partially solidified to wax upon standing at
room temperature for a few days (160 mg, 534 mmol, 67%): Rf=
0.49 (CHCl3/EtOAc, 8:1), c.f. Rf=0.90 (21a); mp: 1208C; IR (KBr) n ˜ =
3700–2500, 3000–2800, 1615, 1590, 1440 cm
 1;
1H NMR (400 MHz,
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MED B. V. L. Potter et al.[D6]DMSO) d=0.90 (t, J~7 Hz, 3H, CH3), 1.39 (m, 4H), 1.51 (m, 2H),
1.59 (m, 2H), 1.75 (m, 2H), 1.86 (m, 2H), 2.93 (m, 2H), 3.12 (m, 2H),
4.33 (t, J=6.6 Hz, 2H, OCH2), 6.91 (dd, J=2.3 and 8.9 Hz, 1H,
C2-H), 6.97 (d, J=2.3 Hz, 1H, C4-H), 7.88 (d, J=8.9 Hz, 1H, C1-H)
and 9.81 ppm (brs, 1H, ex. with D2O, OH); MS (FAB
+): m/z (%):
300.2 (100) [M+H]
+, 230.1 (30); MS (FAB
 ) m/z (%) 452.2 (7)
[M+NBA]
 , 298.2 (100) [M H]
 , 228.1(17); HRMS-FAB
+: m/z [M+
H]
+ calcd for C19H26NO2: 300.1964, found: 300.1962; Anal. calcd for
C19H25NO2: C 76.22, H 8.42, N 4.68, found: C 75.9, H 8.50, N, 4.66.
6-(Pentyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quinolin-3-yl
sulfamate (21). Compound 21b (140 mg, 468 mmol) in anhydrous
DMF (10 mL) was sulfamoylated in a similar manner to 16a. The
crude light-brown syrup (175 mg) that was obtained was fractio-
nated on silica with EtOAc/hexane (1:3 ! 1:2). The second fraction
that was collected gave 21 as a yellow syrup that solidified to wax
upon standing at room temperature overnight (87 mg, 230 mmol,
49%): Rf=0.41 (EtOAc/hexane, 1:2), c.f. Rf=0.54 (21b); mp: 103–
1078C;
1H NMR (400 MHz,[ D 6]DMSO) d=0.92 (t, J=7 Hz, 3H, CH3),
1.41 (m, 4H), 1.54 (m, 2H), 1.61 (m, 2H), 1.78 (m, 2H), 1.89 (m, 2H),
3.01 (m, 2H), 3.22 (m, 2H), 4.40 (t, J=6.5 Hz, 2H, OCH2), 7.30 (dd,
J=2.3 and 8.9 Hz, 1H, C2-H), 7.59 (d, J=2.3 Hz, 1H, C4-H), 8.06 (s,
2H, ex. with D2O, OSO2NH2) and 8.17 ppm (d, J=9 Hz, 1H, C1-H);
MS (FAB
+): m/z (%): 379.2 (100) [M+H]
+, 300.2 (5) [M+
H HNSO2]
+;M S( F A B
 ): m/z (%): 377.1 (100) [M H]
 , 298.2 (11)
[M H2NSO2]
 , 77.9 (52); HRMS-FAB
+: m/z [M+H]
+ calcd for
C19H27N2O4S: 379.1692, found: 379.1691; Anal. calcd for
C19H26N2O4S: C 60.30, H 6.92, N 7.40, found: C 60.5, H 7.05, N 7.34.
3-(Benzyloxy)-5-(3-phenylpropyl)-8,9,10,11-tetrahydro-5H-cyclo-
hepta[c]quinolin-6(7H)-one (22a) and 3-(benzyloxy)-6-(3-phenyl-
propoxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]quino-line (23a).
NaH (60% in mineral oil, 65 mg, 1.62 mmol) was added to a solu-
tion of 17 (500 mg, 1.57 mmol) in DMF (40 mL) at room tempera-
ture cautiously followed by 1-bromo-3-phenylpropane (0.25 mL,
1.65 mmol) 15 min later after the evolution of H2 had ceased. The
reaction mixture was heated at 1008C for 1 h and then concentrat-
ed in vacuo after cooling to room temperature. The crude material
that was obtained was dissolved in EtOAc (100 mL) and the result-
ing mixture was washed with brine (4 50 mL), dried (MgSO4), fil-
tered and evaporated to give a yellow syrup which was fractionat-
ed on silica eluting first with CHCl3/hexane (2:1 ! 4:1 gradient),
then CHCl3 followed by CHCl3/EtOAc (2:1 ! 1:2 gradient). The first
fraction that was collected upon evaporation gave 23a as a light-
yellow syrup (287 mg, 656 mmol, 42%): Rf=0.71 (CHCl3/hexane,
2:1), c.f. Rf<0.1 (17);
1H NMR (400 MHz,[ D 6]DMSO): d=1.57 (m,
4H), 2.09 (quintet, J=7 Hz, 2H, OCH2CH2CH2Ph), 2.77 (t, 2H,
CH2CH2Ph), 2.98 (m, 2H), 3.16 (m, 2H), 4.35 (t, J=6.3 Hz, 2H,
OCH2CH2), 5.23 (s, 2H, OCH2Ph), 7.09 (dd, J=2.5 and 9 Hz, 1H, C2-
H), 7.34 (m, 11H, C4-H and 2 Ar) and 7.98 ppm (d, J=9 Hz, 1H,
C1-H); MS (FAB
+): m/z (%): 438.4 (20) [M+H]
+, 319.3 (14) [M+H-
CH2CH2CH2Ph]




+ calcd for C30H32NO2: 438.2433, found: 438.2438. The
second fraction that was collected upon evaporation gave a clear
syrup (373 mg, 852 mmol, 55%) that was recrystallised from EtOAc/
hexane (1:15, ~32 mL) to give 22a as light-beige rod-shaped crys-
tals (240 mg): Rf=0.38 (CHCl3/hexane, 2:1), c.f. Rf<0.1 (17); mp:
120–1228C;
1H NMR (400 MHz,[ D 6]DMSO) d=1.45 (m, 2H), 1.56
(m, 2H), 1.83 (m, 4H), 2.71 (t, J=7.4 Hz, 2H, CH2CH2Ph), 2.89 (m,
2H), 2.98 (m, 2H), 4.22 (t, J=7.6 Hz, 2H, NCH2), 5.17 (s, 2H,
OCH2Ph), 6.83 (d, J=2.3 Hz, 1H, C4-H), 6.93 (dd, J=2.3 and 8 Hz,
1H, C2-H), 7.34 (m, 10H, Ar) and 7.86 ppm (d, J=9 Hz, 1H, C1-H);
MS (FAB
+): m/z (%): 438.4 (100) [M+H]





+ calcd for C30H32NO2:
438.2433, found: 438.2423. Anal. calcd for C30H31NO2: C 82.35, H
7.14, N, 3.20, found: C 82.7, H 7.14, N 3.43.
3-Hydroxy-5-(3-phenylpropyl)-8,9,10,11-tetrahydro-5H-cyclohep-
ta[c]quinolin-6(7H)-one (22b). A solution of 22a (300 mg,
686 mmol) in absolute EtOH (30 mL) was debenzylated by hydroge-
nation in similar manner to 18a in the presence of Pd/C (10%,
60 mg). The crude solid that resulted (205 mg, 590 mmol, 86%) was
recrystallised from toluene/hexane (8:3) to give 22b as creamy
crystals (150 mg): Rf=0.68 (CHCl3/EtOAc, 4:1), c.f. Rf=0.91 (22a);
mp: 182–1868C;
1H NMR (400 MHz,[ D 6]DMSO): d=1.45 (m, 2H),
1.56 (m, 2H), 1.81 (m, 2H), 1.90 (quintet, J=7.8 Hz, 2H,
NCH2CH2CH2Ph), 2.73 (t, J=7.8 Hz, 2H, CH2Ph), 2.88 (m, 2H), 2.96
(m, 2H), 4.18 (t, J=7 Hz, 2H, NCH2), 6.72 (dd, J=2.3 and 8.9 Hz,
1H, C2-H), 6.78 (d, J=2 Hz, 1H, C4-H), 7.25 (m, 5H, Ph), 7.76 (d, J=
8.9 Hz, 1H, C1-H) and 10.1 (brs, 1H, ex. with D2O, OH); MS (FAB
+):
m/z (%): 348.3 (100) [M+H]
+, 243.2 (18); MS (FAB
 ): m/z (%):
500.3(47) [M+NBA]




+ calcd for C23H26NO2: 348.1964, found: 348.1964.
6-Oxo-5-(3-phenylpropyl)-6,7,8,9,10,11-hexahydro-5H-cyclohep-
ta[c]quinolin-3-yl sulfamate (22). Compound 22b (100 mg,
288 mmol) in anhydrous DMF (10 mL) was sulfamoylated in a simi-
lar manner to 16a. The crude light-yellow residue (122 mg) ob-
tained was fractionated on silica with CHCl3/EtOAc (8:1). The
second fraction that was collected gave a light-yellow syrup that
solidified on standing overnight to give 22 as a white solid (65 mg,
152 mmol, 53%). Recrystallisation from hot CHCl3/hexane (5:4) gave
22 as fine white crystals (39 mg): Rf=0.23 (CHCl3/EtOAc, 8:1), c.f.
Rf=0.43 (22b); mp: 176–1798C; IR (KBr) n ˜ =3650–3000, 3000–
2800, 1610, 1560, 1380, 1190 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO)
d=1.45 (m, 2H), 1.56 (m, 2H), 1.83 (m, 2H), 1.91 (m, 2H), 2.71 (t,
J=7.7 Hz, 2H, CH2Ph), 2.92 (m, 2H), 3.03 (m, 2H), 4.24 (t, J=7.7 Hz,
2H,CH 2N), 7.22 (m, 6H, C2-H and Ar), 7.35 (d, J=2.2 Hz, 1H, C4-H),
8.03 (d, J=8.8 Hz, 1H, C1-H) and 8.08 ppm (brs, 2H, ex. with D2O,
OSO2NH2); MS (FAB
+): m/z (%): 427.2 (100) [M+H]
+, 346.2 (25)
[M H2NSO2]
+;M S( F A B
 ): m/z (%): 425.1(100) [M H]




+ calcd for C23H27N2O4S:
427.1620, found 427.1695. Anal. calcd for C23H26N2O4S: C 64.77, H
6.14, N 6.57, found: C 64.2, H 6.13, N 6.65.
6-(3-Phenylpropoxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]qui-
nolin-3-ol (23b). A solution of 23a (255 mg, 583 mmol) in a mix-
ture of absolute EtOH (30 mL) and THF (10 mL) was debenzylated
by hydrogenation in similar manner to 18a in the presence of Pd/
C (10%, 51 mg). The crude yellow syrup that was obtained solidi-
fied on standing overnight to give 23b as a yellow wax (182 mg,
524 mmol, 90%): Rf=0.61 (CHCl3/EtOAc, 4:1), c.f. Rf=0.88 (23a);
mp: ~1358C; IR (KBr) n ˜ =3700–2500, 3000–2800, 1615, 1590, 1420,
1330, 1200 cm
 1;
1H NMR (400 MHz,[ D 6]DMSO) d=1.57 (m, 4H),
1.86 (m, 2H), 2.08 (m, 2H, CH2CH2CH2Ph), 2.77 (t, J=7.5 Hz, 2H,
CH2Ph),2.95 (m, 2H), 3.13 (m, 2H), 4.33 (t, J=6.4 Hz, 2H, OCH2),
6.91 (dd, J=2.7 and 8.9 Hz, 1H, C2-H), 6.95 (d, J=2.3 Hz, 1H, C4-
H), 7.25 (m, 5H, Ar), 7.88 (d, J=8.9 Hz, 1H, C1-H) and 9.82 (brs, 1H,
ex. with D2O, OH); MS (FAB
+): m/z (%): 348.3 (100) [M+H]
+, 229.3
(40) [M+H CH2CH2CH2Ph]
+;M S( F A B
 ): m/z (%): 346.3 (100)
[M H]
 , 275.2 (40), 181.2 (50); HRMS-FAB
+: m/z [M+H]
+ calcd for
C23H26NO2: 348.1964, found: 348.1969.
6-(3-Phenylpropoxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]qui-
nolin-3-yl sulfamate (23). Compound 23b (135 mg, 389 mmol) in
anhydrous DMF (10 mL) was sulfamoylated in a similar manner to
16a. The crude light-brown syrup (175 mg) that obtained was frac-
tionated on silica with EtOAc/hexane (1:3 ! 1:2). The second frac-
tion that was collected gave 23 as a yellow syrup that solidified to
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Irosustat SARwax upon standing at room temperature overnight (87 mg,
230 mmol, 49%): Rf=0.41 (EtOAc/hexane, 1:2), c.f. Rf=0.54 (23b);
mp: 103–1078C;
1H NMR (400 MHz,[ D 6]DMSO): d=0.92 (t, J=
7 Hz, 3H, CH3), 1.41 (m, 4H), 1.54 (m, 2H), 1.61 (m, 2H), 1.78 (m,
2H), 1.89 (m, 2H), 3.01 (m, 2H), 3.22 (m, 2H), 4.40 (t, J=6.5 Hz, 2H,
OCH2), 7.30 (dd, J=2.3 and 8.9 Hz, 1H, C2-H), 7.59 (d, J=2.3 Hz,
1H, C4-H), 8.06 (s, 2H, ex. with D2O, OSO2NH2) and 8.17 ppm (d,
J=9 Hz, 1H, C1-H); MS (FAB
+): m/z (%): 379.2 (100) [M+H]
+, 300.2
(5) [M+H HNSO2]
+;M S( F A B
 ): m/z (%): 377.1 (100) [M H]
 ,
298.2 (11) [M H2NSO2]
 , 77.9 (52); HRMS-FAB
+: m/z [M+H]
+ calcd
for C19H27N2O4S: 379.1692, found: 379.1691. Anal. calcd for
C19H26N2O4S: C 60.30, H 6.92, N 7.40, found: C 60.5, H 7.05, N 7.34.
3-Amino-8,9,10,11-tetrahydro-5H-cyclohepta[c]quinolin-6(7H)-
one (24a). A mixture of 1,3-phenylenediamine (5.0 g, 46.22 mmol)
and methyl 2-oxo-1-cycloheptane carboxylate (7.9 g, 46.22 mmol)
was heated at 1508C overnight. The yellow sludge that formed
was cooled to room temperature and diluted with Et2O to give a
yellow suspension which was filtered. The beige precipitate collect-
ed (3.91 g) was recrystallised from hot iPrOH to give 24a as a
wool-like fluff (1.59 g, 6.98 mmol, 15%): mp: 290–3008C (dec); IR
(KBr) n ˜ =3460, 3360, 2920, 2850, 1650, 1620 cm
 1;
1H NMR
(400 MHz,[ D 6]DMSO): d=1.42 (m, 2H), 1.54 (m, 2H), 1.80 (m, 2H),
2.78 (m, 2H, C7-H2), 2.87 (m, 2H, C11-H2), 5.63 (brs, ~2H, ex. with
D2O, NH2), 6.37 (d, J=2.1 Hz, 1H, C4-H2), 6.64 (dd, J=2.1 and
8.9 Hz, 1H, C2-H2), 7.46 (d, J=8.8 Hz, 1H, C1-H2) and 11.2 (brs, 1H,
exchanged with D2O, CONH). Anal. calcd for C14H16N2O: C 73.66, H
7.06, N 12.27, found: C 73.7, H 7.21, N, 12.1.
6-Oxo-6,7,8,9,10,11-hexahydro-5H-cyclohepta[c]quinolin-3-ylsul-
famide (24). To a solution of 24a (300 mg; 1.31 mmol) and 2,6-di-
tert-butyl-4-methylpyridine (270 mg, 1.31 mmol) in anhydrous DMF
(20 mL) at 08C under N2 was added sulfamoyl chloride (~0.69m in
toluene,
[19] ~3–5 equiv, evaporated down to ~1 mL prior to addi-
tion). After stirring at room temperature under N2 overnight, the
reaction mixture was diluted with EtOAc (~150 mL) and the organ-
ic layer washed with brine (5 100 mL). After drying with MgSO4
and filtering, the filtrate was evaporated, during which time the
precipitation of 24 occurred. Collection and air drying of the pre-
cipitate gave 24 as a white powder (113 mg; 28%): Rf=0.46
(CHCl3/EtOAc, 4:1); mp: 183–1858C; IR (KBr) n ˜ =3700–2700, 3360,
3280, 2920, 2840, 1630, 1340, 1160 cm
 1;
1H NMR (270 MHz;
[D6]DMSO): d=1.44 (m, 2H), 1.56 (m, 2H), 1.83 (m, 2H), 2.81 (m,
2H, C7-CH2), 2.94 (m, 2H, C11-CH2), 7.03 (dd, J=2.2 and 8.8 Hz, 1H,
C2-H), 7.10 (d, J=2.1 Hz, 1H, C4-H), 7.13 (brs, 2H, ex. with D2O,
H2NSO2NH), 7.73 (d, J=9 Hz, 1H, C1-H), 9.81 (s, 1H, ex. with D2O,
H2NSO2NH) and 11.52 (s, 1H, ex. with D2O, CONH); MS (FAB
+): m/z
(%): 308.1 (100) [M+H]
+;M S( F A B




+ calcd for C14H18N3O3S: 308.1069, found:
308.1055; Anal. calcd for C14H17N3O3S: C 54.71, H 5.57, N 13.67,
found: C 54.5, H 5.60, N 13.5.
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